## **Supporting Information**

# Enantioselective synthesis of 2-amino-4*H*-chromene derivatives with antifungal activities on phytopathogenic fungi

Man Zhang <sup>a</sup>,<sup>‡</sup> Yifan Ru <sup>a</sup>,<sup>‡</sup> Shilin Wang <sup>a</sup>, Wen Fu <sup>a</sup>, Tianyu Li <sup>a</sup>, Xusheng Shao <sup>a</sup>, Zhong Li <sup>a</sup>, Wu-Lin Yang <sup>a</sup>

<sup>a</sup> Shanghai Key Laboratory of Chemical Biology & School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, P. R. China Email: yangwl@ecust.edu.cn
 <sup>‡</sup>These authors contributed equally.

## **Table of Contents**

1.	General information	<b>S2</b>
2.	Optimization study	<b>S</b> 3
3.	Synthesis and characterization data of 2-amino-4 <i>H</i> -chromene derivatives	<b>S</b> 5
4.	Gram-scale preparation of products 47 and 63	S35
5.	Synthetic transformations of product 47	<b>S36</b>
6.	Antifungal activities evaluation	<b>S38</b>
7.	References	<b>S41</b>
8.	<sup>1</sup> H NMR, <sup>13</sup> C NMR and <sup>19</sup> F NMR spectra	S42
9.	HPLC chromatograms	S121

#### 1. General information

<sup>1</sup>H NMR spectra were recorded on a Bruker DPX 400 MHz spectrometer in CDCl<sub>3</sub> Chemical shifts are reported in ppm with the internal CDCl<sub>3</sub> signal at 7.26 ppm as a standard. The spectra are interpreted as: s, singlet; brs, broad singlet; d, doublet; t, triplet; m, multiplet; dd, double doublet; ddd, double doublet; td, triple doublet; coupling constant(s) J are reported in Hz and relative integrations are reported. <sup>13</sup>C NMR (100 MHz) spectrum were recorded on a Bruker DPX 400 MHz spectrometer in CDCl<sub>3</sub>. Chemical shifts are reported in ppm with the internal chloroform signal at 77.16 ppm as a standard; <sup>19</sup>F NMR (376 MHz) spectra were recorded on a Bruker DPX 400 MHz spectrometer in CDCl<sub>3</sub> and referenced relative to CFCl<sub>3</sub>. Optical rotations were measured on an AUTOPOL V. Enantiomeric excesses were determined by analysis of HPLC traces, obtained by using Chiralpak AS-H, AD-H, IC, columns with nhexane and ethanol as solvents (Chiralpak AS-H, AD-H, IC, were purchased from Daicel Chiral Technologies (China) Co., Ldq.). Melting points were obtained in open capillary tubes using Buchi melting point B540 which were uncorrected. High-resolution mass spectra (HRMS) were recorded on a Waters GCT Premier mass spectrometer using EI-TOF and ESI-TOF (electron ionization-time of flight). Commercially available materials purchased from Adamas-beta and Bidepharm, which were used as received. Solvent was purified according to the procedure from *Purification of Laboratory Chemicals.*  $[Ir(cod)Cl]_2$  and malononitrile was purchased from Bidepharm. Carreira's ligand (S)-L1 was prepared according to the literature procedure.<sup>[1]</sup> Substrates 2-(1-hydroxyallyl)phenols  $(\pm)$ -1<sup>[2]</sup> and (E)-1-(methylthio)-2-nitroenamines 2<sup>[3]</sup> were prepared according to the literature procedures.

## 2. Optimization study

OH + 1a	MeS NO <sub>2</sub> -	[Ir(cod)Cl] <sub>2</sub> (4 mol%) (S)- <b>L1</b> (16 mol%) Ce(OTf) <sub>3</sub> (20 mol%) solvent, rt	NO <sub>2</sub> NHPh 3	O P-N (S)-L1
entry <sup>[a]</sup>	solvent	additive	yield (%) <sup>[</sup>	<sup>b]</sup> ee (%) <sup>[c]</sup>
1	$CH_2Cl_2$	no	98	96
2	THF	no	83	95
3	CH <sub>3</sub> CN	no	68	92
4	DCE	no	91	95
5	toluene	no	84	95
6	$CH_2Cl_2$	3Å MS	59	85
7	$CH_2Cl_2$	4Å MS	64	84
8	$CH_2Cl_2$	5Å MS	74	86

## Table S1 Screening of the solvents and additive

[a] Unless others stated, the reactions were performed with **2a** (0.10 mmol), **1a** (0.20 mmol), [Ir(cod)Cl]<sub>2</sub> (4 mol %), (S)-L1 (16 mol %), and Ce(OTf)<sub>3</sub> (20 mol %) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) at room temperature. [b] Yield of isolated product **3**. [c] The ee value was determined by chiral HPLC analysis.

## Table S2Optimization of the reaction conditions

L 1a	он <sub>+</sub> он <b>т</b>	[Ir(cod)Cl] <sub>2</sub> (4 mo NC CN <u>(S)-L1 (16 mol%</u> acid (20 mol% solvent, rt	$ \stackrel{ \%)}{\xrightarrow{6}} \qquad \overbrace{63}}^{ \%)} \qquad \overbrace{63}$		0.P-N (S)-L1	
-	entry <sup>[a]</sup>	acid promoter	solvent	yield (%) <sup>[b]</sup>	ee (%) <sup>[c]</sup>	
_	1	Ce(OTf) <sub>3</sub>	CH <sub>2</sub> Cl <sub>2</sub>	40	56	
	2	Yb(OTf) <sub>3</sub>	$CH_2Cl_2$	59	56	
	3	Yb(OTf) <sub>3</sub>	CH <sub>3</sub> CN	33	81	
	4	Yb(OTf) <sub>3</sub>	toluene	54	50	
	5	Yb(OTf) <sub>3</sub>	1,4-dioxane	53	82	
	6	Yb(OTf) <sub>3</sub>	THF	56	82	
	7	CF <sub>3</sub> CO <sub>2</sub> H	THF	32	69	
	8	o-NO <sub>2</sub> C <sub>6</sub> H <sub>4</sub> CO <sub>2</sub> H	THF	42	86	
	9	Ce(OTf) <sub>3</sub>	THF	50	83	
	10	La(OTf) <sub>3</sub>	THF	48	81	

11	Lu(OTf) <sub>3</sub>	THF	85	83
12	Dy(OTf) <sub>3</sub>	THF	39	81
13	Er(OTf) <sub>3</sub>	THF	46	79
14	Nd(OTf) <sub>3</sub>	THF	73	88

[a] Unless others stated, the reactions were performed with malononitrile (0.10 mmol), **1a** (0.20 mmol), [Ir(cod)Cl]<sub>2</sub> (4 mol %), (*S*)-**L1** (16 mol %), and Nd(OTf)<sub>3</sub> (20 mol %) in THF (1.5 mL) at room temperature. [b] Yield of isolated product **63**. [c] The ee value was determined by chiral HPLC analysis.



Scheme S1 Unsuccessful reactions

#### 3. Synthesis and characterization data of 2-amino-4H-chromene derivatives



**General procedure A**: Under a nitrogen atmosphere, a flame dried 10 mL Schlenk tube was charged with  $[Ir(cod)Cl]_2$  (2.7 mg, 0.004 mmol, 4 mol%), Carreira's ligand (*S*)-L1 (8.2 mg, 0.016 mmol, 16 mol%). After the tube was evacuated and backfilled with nitrogen, freshly distilled CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) was added, then stirred at room temperature for 15 minutes while the solution turned dark red. Then, 2-(1-hydroxyallyl)phenols 1 (0.2 mmol, 2.0 equiv) were added and the reaction mixture immediately turned light yellow. 1-(Methylthio)-2-nitroenamines 2 (0.1 mmol, 1.0 equiv) and Ce(OTf)<sub>3</sub> (11.74 mg, 0.02 mmol, 20 mol%) were added sequentially. The reaction mixture was stirred at room temperature until 2 were consumed (monitored by TLC), which was directly purified by flash column chromatography silica gel (CH<sub>2</sub>Cl<sub>2</sub> or petroleum ether/ethyl acetate = 4/1) to afford products **3-62**.



(*S*)-3-Nitro-*N*-phenyl-4-vinyl-4*H*-chromen-2-amine (3): Following the general procedure A, compound **3a** was obtained as a yellow solid in 98% yield (28.8 mg), 96% ee;  $R_f = 0.6$  (CH<sub>2</sub>Cl<sub>2</sub>); m.p: 105 – 107 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  12.26 (brs, 1H), 7.45 – 7.42 (m, 4H), 7.32 – 7.25 (m, 3H), 7.24 – 7.19 (m, 1H), 7.08 (d, *J* = 8.0 Hz, 1H), 5.92 (ddd, *J* = 16.7, 10.0, 6.6 Hz, 1H), 5.10 (d, *J* = 9.8 Hz, 1H), 5.04 (d, *J* = 16.8 Hz, 1H), 5.02 (d, *J* = 6.6 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  156.9, 148.1, 137.2, 135.2, 129.7, 129.5(2C), 128.6, 126.6, 126.1, 123.3(1), 123.3(0) (2C), 116.3, 115.8, 108.2, 39.6. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>: 294.0999, found: 294.1006; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +19.0 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 8.466 min (minor), 15.350 min (major).



(*S*)-*N*-(3-Fluorophenyl)-3-nitro-4-vinyl-4*H*-chromen-2-amine (4): Following the general procedure **A**, compound 4 was obtained as a yellow solid in 83% yield (25.9 mg), 95% ee;  $R_f = 0.6 (CH_2Cl_2)$ ; m.p: 136 – 138 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  12.26 (brs, 1H), 7.45 – 7.35 (m, 1H), 7.33 – 7.24 (m, 4H), 7.17 (d, *J* = 8.0 Hz, 1H), 7.12 (d, *J* = 7.9 Hz, 1H), 7.02 – 6.97 (m, 1H), 5.91 (ddd, *J* = 16.8, 10.0, 6.6 Hz, 1H), 5.12 (d, *J* = 10.0 Hz 1H), 5.07 (d, *J* = 17.1 Hz, 1H),

5.01 (d, J = 6.6 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  163.1 (d, <sup>1</sup> $J_{C-F} = 246.9$  Hz), 156.6 148.0, 137.1, 136.8 (d, <sup>3</sup> $J_{C-F} = 10.4$  Hz), 130.7 (d, <sup>3</sup> $J_{C-F} = 9.2$  Hz), 129.8, 128.7, 126.3, 123.2, 118.7 (d, <sup>4</sup> $J_{C-F} = 3.2$  Hz), 116.1 (d, <sup>2</sup> $J_{C-F} = 32.8$  Hz), 113.3 (d, <sup>2</sup> $J_{C-F} = 21.3$  Hz), 110.6, 110.4, 108.7, 39.5. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -110.48 – -110.55(m). HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub>FN<sub>2</sub>O<sub>3</sub>: 312.0905, found: 312.0912; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +22.9 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 7.218 min (minor), 13.914 min (major).



(*S*)-*N*-(3-Chlorophenyl)-3-nitro-4-vinyl-4*H*-chromen-2-amine (5): Following the general procedure **A**, compound **5** was obtained as a yellow solid in 78% yield (25.6 mg), 89% ee; R<sub>f</sub> = 0.6 (CH<sub>2</sub>Cl<sub>2</sub>); m.p: 131 – 133 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  12.18 (brs, 1H), 7.49 (s, 1H), 7.39 – 7.35(m, 1H), 7.33 – 7.20 (m, 5H), 7.09 (d, *J* = 7.8 Hz, 1H), 5.90 (ddd, *J* = 16.7, 10.0, 6.6 Hz, 1H), 5.10 (d, *J* = 10.3 Hz, 1H), 5.04 (d, *J* = 17.2 Hz, 1H), 5.00 (d, *J* = 6.6 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  156.6, 147.9, 137.1, 136.5, 135.1, 130.5, 129.7, 128.7, 126.5, 126.3, 123.3, 123.2, 121.2, 116.3, 115.9, 108.7, 39.5. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>35</sup>ClN<sub>2</sub>O<sub>3</sub>: 328.0610, found: 328.0612; C<sub>17</sub>H<sub>13</sub><sup>37</sup>ClN<sub>2</sub>O<sub>3</sub>: 330.0580, found: 330.0585; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +30.2 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 7.182 min (minor), 12.817 min (major).



(*S*)-*N*-(4-Fluorophenyl)-3-nitro-4-vinyl-4*H*-chromen-2-amine (6): Following the general procedure **A**, compound **6** was obtained as a yellow solid in 95% yield (29.7 mg), 90% ee; R<sub>f</sub> = 0.6 (CH<sub>2</sub>Cl<sub>2</sub>); m.p: 142 – 144 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  12.17 (brs, 1H), 7.40 (dd, *J* = 9.0, 4.7 Hz, 2H), 7.32 – 7.24 (m, 3H), 7.17 – 7.13 (m, 2H), 7.04 (d, *J* = 8.2 Hz, 1H), 5.91 (ddd, *J* = 16.8, 10.0, 6.6 Hz, 1H), 5.10 (d, *J* = 10.0 Hz, 1H), 5.06 (d, *J* = 16.4 Hz, 1H), 5.01 (d, *J* = 6.6 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  161.0 (d, <sup>1</sup>*J* <sub>*C*-*F*</sub> = 247.2 Hz), 156.9, 148.1, 137.1, 131.1 (d, <sup>4</sup>*J* <sub>*C*-*F*</sub> = 3.2 Hz), 129.8, 128.6, 126.2, 125.4 (d, <sup>3</sup>*J* <sub>*C*-*F*</sup> = 8.4 Hz)(2C), 123.3, 116.5, 116.3 (d, <sup>2</sup>*J* <sub>*C*-*F*</sup> = 8.6 Hz) (2C), 115.9, 108.2, 39.6. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  - 114.62 – -114.68 (m). HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub>FN<sub>2</sub>O<sub>3</sub>: 312.0905, found: 312.0908; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +21.7 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 10.287 min (minor), 21.105 min (major).</sub></sub>



(*S*)-*N*-(4-Chlorophenyl)-3-nitro-4-vinyl-4*H*-chromen-2-amine (7): Following the general procedure **A**, compound 7 was obtained as a yellow solid in 89% yield (29.1 mg), 94% ee; R<sub>f</sub> = 0.6 (CH<sub>2</sub>Cl<sub>2</sub>); m.p: 129 – 131 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 12.20 (brs, 1H), 7.42 – 7.35(m, 4H), 7.29 – 7.27 (m, 2H), 7.25 – 7.18 (m, 1H), 7.07 (d, J = 7.8 Hz, 1H), 5.90 (ddd, J = 16.7, 10.0, 6.6 Hz, 1H), 5.09 (d, J = 9.8 Hz, 1H), 5.04 (d, J = 16.8 Hz, 1H), 4.99 (d, J = 6.6 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 156.6, 147.9, 137.1, 133.8, 132.0, 129.7, 129.6(2C), 128.6, 126.2, 124.5(2C), 123.1, 116.2, 115.9, 108.4, 39.5. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>35</sup>ClN<sub>2</sub>O<sub>3</sub>: 328.0610, found: 328.0613; C<sub>17</sub>H<sub>13</sub><sup>37</sup>ClN<sub>2</sub>O<sub>3</sub>: 330.0580, found: 330.0579; [α]<sub>D</sub><sup>25</sup> = +29.7 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 9.144 min (minor), 19.878 min (major).



(*S*)-*N*-(**4-Bromophenyl**)-**3-nitro-4-vinyl-4***H***-chromen-2-amine (<b>8**): Following the general procedure **A**, compound **8** was obtained as a yellow solid in 89% yield (33.2 mg), 98% ee;  $R_f = 0.6 (CH_2Cl_2)$ ; m.p: 129 – 131 °C; <sup>1</sup>**H** NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  12.19 (brs, 1H), 7.57 (d, *J* = 8.7 Hz, 2H), 7.33 – 7.25 (m, 5H), 7.07 (d, *J* = 7.7 Hz, 1H), 5.91 (ddd, *J* = 16.8, 10.0, 6.6 Hz, 1H), 5.10 (d, *J* = 10.7 Hz, 1H), 5.05 (d, *J* = 17.6 Hz, 1H), 5.01 (d, *J* = 6.6 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  156.7, 148.1, 137.1, 134.4, 132.7(2C), 129.8, 128.7, 126.3, 124.9(2C), 123.2, 119.9, 116.3, 115.9, 108.6, 39.6.HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>79</sup>BrN<sub>2</sub>O<sub>3</sub>: 372.0104, found: 372.0111; C<sub>17</sub>H<sub>13</sub><sup>81</sup>BrN<sub>2</sub>O<sub>3</sub>: 374.0084, found: 374.0090; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +19.8 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); **HPLC** (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 9.542 min (minor), 23.178 min (major).

The preparation and X-ray analysis of the single crystal: Compound 8 (98% ee, 10.0 mg) was dissolved in 1.0 mL of acetone in a screw-top vial and drops of hexane were added. The lid was then loosely screwed on the vial, and a single crystal was obtained by natural volatilization at room temperature. The data set was collected by a Bruker APEX-II CCD at 293(2) K equipped with Mo radiation source (K $\alpha$  = 0.71073 Å). Applied with multi-scan absorption correction, the structure solution was solved and refinement was processed by SHELXTL program package. CCDC 2342669 contains the supplementary crystallographic data, and can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html.



*Figure S1.* The thermal ellipsoid plot for X-ray structure of compound **8** with the ellipsoid contour at 30% probability levels

The crystallographic data of compound 8			
Identification code	mo_dd22075_0m		
Empirical formula	$C_{17}H_{13}BrN_2O_3$		
Formula weight	373.20		
Temperature	293(2) K		
Wavelength	0.71073 Å		
Crystal system	Orthorhombic		
Space group	P 21 21 21		
Unit cell dimensions	a = 4.8026(3)  Å	a= 90 °.	
	b = 10.1124(6) Å	b= 90 °.	
	c = 31.8117(19) Å	g= 90 °.	
Volume	1544.96(16) Å <sup>3</sup>		
Z	4		
Density (calculated)	1.604 Mg/m <sup>3</sup>		
Absorption coefficient	2.677 mm <sup>-1</sup>		
F(000)	752		
Crystal size	0.180 x 0.120 x 0.070 mm <sup>3</sup>		
Theta range for data collection	2.783 to 25.997 °.		
Index ranges	-5<=h<=5, -9<=k<=12, -39<=l<=37		
Reflections collected	7304		
Independent reflections	3004 [R(int) = 0.0523]		
Completeness to theta = $25.242^{\circ}$	99.5 %		

Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	0.7456 and 0.4356
Refinement method	Full-matrix least-squares on F <sup>2</sup>
Data / restraints / parameters	3004 / 0 / 208
Goodness-of-fit on F <sup>2</sup>	1.001
Final R indices [I>2sigma(I)]	R1 = 0.0391, $wR2 = 0.0895$
R indices (all data)	R1 = 0.0533, $wR2 = 0.0974$
Absolute structure parameter	0.047(15)
Extinction coefficient	n/a
Largest diff. peak and hole	0.460 and -0.372 e.Å <sup>-3</sup>



(*S*)-3-Nitro-*N*-(**p-tolyl**)-4-vinyl-4*H*-chromen-2-amine (9): Following the general procedure **A**, compound **9** was obtained as a yellow solid in 98% yield (30.2 mg), 85% ee;  $R_f = 0.6$  (CH<sub>2</sub>Cl<sub>2</sub>); m.p: 109 – 111 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  12.25 (brs, 1H), 7.31 – 7.18(m, 7H), 7.05 (d, J = 9.4 Hz, 1H), 5.91 (ddd, J = 16.6, 9.9, 5.9 Hz, 1H), 5.08 (d, J = 9.8 Hz, 1H), 5.03 (d, J = 16.4 Hz 1H), 4.99 (d, J = 6.6 Hz, 1H), 2.38 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  156.8, 148.1, 137.1, 136.6, 132.5, 129.9(2C), 129.6, 128.5, 125.9, 123.20, 123.1(2C), 116.2, 115.6, 107.9, 39.5, 21.1. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>: 308.1155, found: 308.1158; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +24.5 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); **HPLC** (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 9.176 min (minor), 14.421 min (major).



(*S*)-*N*-(3-Chloro-4-methylphenyl)-3-nitro-4-vinyl-4*H*-chromen-2-amine (10): Following the general procedure **A**, compound 10 was obtained as a yellow solid in 89% yield (30.4 mg), 93% ee;  $R_f = 0.6$  (CH<sub>2</sub>Cl<sub>2</sub>); m.p: 114 – 116 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  12.17 (brs, 1H), 7.50 (d, J = 2.2 Hz, 1H), 7.33 – 7.25 (m, 3H), 7.24 (d, J = 5.3 Hz, 1H), 7.23 – 7.16 (m, 1H), 7.12 – 7.05 (m, 1H), 5.91 (ddd, J = 16.8, 10.0, 6.6 Hz, 1H), 5.10 (d, J = 9.9 Hz, 1H), 5.04 (d, J = 18.8 Hz, 1H), 5.01 (d, J = 6.5 Hz, 1H), 2.41 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  156.7, 148.0, 137.1, 134.9, 134.5, 133.9, 131.5, 129.7, 128.7, 126.2, 123.8, 123.2, 121.5, 116.3, 115.9, 108.4, 39.5, 19.8. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>15</sub><sup>35</sup>ClN<sub>2</sub>O<sub>3</sub>: 342.0766, found: 342.0769; C<sub>18</sub>H<sub>15</sub><sup>37</sup>ClN<sub>2</sub>O<sub>3</sub>: 344.0737, found: 344.0749; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +27.9 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 6.863 min (minor), 11.101 min (major).



(S)-N-(2-Methoxyphenyl)-3-nitro-4-vinyl-4*H*-chromen-2-amine (11): Following the general procedure **A**, compound **11** was obtained as a yellow solid in 95% yield (30.8 mg), 50% ee;  $R_f = 0.6 (CH_2Cl_2)$ ; m.p: 170 – 172 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  12.61 (brs, 1H), 7.82 (d, *J* = 8.0 Hz, 1H), 7.33 – 7.24 (m, 2H), 7.26 – 7.17 (m, 2H), 7.17 – 7.10 (m, 1H), 7.08 – 6.96 (m, 2H), 5.93 (ddd, *J* = 16.7, 10.8, 6.5 Hz, 1H), 5.12 – 4.99 (m, 3H), 3.94 (s, 3H). <sup>13</sup>C NMR (100

MHz, CDCl<sub>3</sub>)  $\delta$  156.7, 150.6, 148.2, 137.4, 129.7, 128.5, 126.6, 126.0, 125.3, 123.5, 122.4, 120.9, 116.3, 115.6, 111.2, 108.3, 56.2, 39.7. **HRMS** (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub>: 324.1105, found: 324.1112; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +16.3 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); **HPLC** (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 8.152 min (minor), 16.787 min (major).



(*S*)-*N*-Benzyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (12): Following the general procedure **A**, compound **12** was obtained as a white solid in 55% yield (16.9 mg), 92% ee;  $R_f = 0.6$  (petroleum ether/ethyl acetate = 4/1); m.p: 148 – 150 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.75 (brs, 1H), 7.43 – 7.30 (m, 5H), 7.30 – 7.22 (m, 2H), 7.24 – 7.14 (m, 1H), 7.08 – 7.01 (m, 1H), 5.88 (ddd, J = 16.7, 10.0, 6.5 Hz, 1H), 5.06 (d, J = 10.1 Hz, 1H), 5.02 (d, J = 16.9 Hz, 1H), 4.95 (d, J = 6.5 Hz, 1H), 4.85 – 4.69 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.2, 148.2, 137.4, 136.4, 129.8, 129.2(2C), 128.5, 128.3, 127.6(2C), 125.9, 123.5, 116.1, 115.5, 107.4, 45.6, 39.6. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>: 308.1155, found: 308.1165; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +3.2 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); **HPLC** (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 13.326 min (minor), 39.044 min (major).



(*S*)-*N*-((6-Chloropyridin-3-yl)methyl)-3-nitro-4-vinyl-4*H*-chromen-2-amine (13): Following the general procedure **A**, compound **13** was obtained as a yellow solid in 65% yield (22.4 mg), 96% ee;  $R_f = 0.5$  (petroleum ether/ethyl acetate = 4/1); m.p: 109 – 111 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.72 (brs, 1H), 8.46 (d, *J* = 2.5 Hz, 1H), 7.71 (dd, *J* = 8.3, 2.5 Hz, 1H), 7.36 (d, *J* = 8.2 Hz, 1H), 7.27 – 7.16 (m, 3H), 7.03 (dd, *J* = 7.8, 1.9 Hz, 1H), 5.85 (ddd, *J* = 16.7, 10.0, 6.6 Hz, 1H), 5.06 (d, *J* = 10.0 Hz, 1H), 5.01 (d, *J* = 17.0 Hz, 1H), 4.92 (d, *J* = 6.6 Hz, 1H), 4.85 – 4.70 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.1, 151.4, 149.1, 147.9, 138.2, 137.2, 131.5, 129.8, 128.7, 126.1, 124.8, 123.2, 115.9, 115.7, 107.8, 42.3, 39.5. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>14</sub><sup>35</sup>ClN<sub>3</sub>O<sub>3</sub>: 343.0719, found: 343.0727; C<sub>17</sub>H<sub>14</sub><sup>37</sup>ClN<sub>3</sub>O<sub>3</sub>: 345.0689, found: 345.0695; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +22.4 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 18.847 min (minor), 48.310 min (major).



(*S*)-*N*-(Furan-2-ylmethyl)-3-nitro-4-vinyl-4*H*-chromen-2-amine (14): Following the general procedure **A**, compound 14 was obtained as a yellow solid in 98% yield (29.2 mg), 91% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 165 – 167 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.58 (brs, 1H), 7.40 (dd, J = 1.8, 0.9 Hz, 1H), 7.32 – 7.26 (m, 2H), 7.22 (d, J = 6.7 Hz, 1H), 7.13 (d, J = 6.7 Hz, 1H), 6.37 – 6.34 (m, 2H), 5.87 (ddd, J = 16.7, 10.0, 6.5 Hz, 1H), 5.06 (d, J = 11.8 Hz, 1H), 5.00 (d, J = 16.8, 1H), 4.94 (d, J = 6.6 Hz, 1H), 4.82 – 4.69 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.9, 149.3, 148.2, 143.1, 137.4, 129.8, 128.5, 125.9, 123.5, 116.2, 115.5, 110.8, 108.6, 107.6, 39.6, 38.4. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>16</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>: 298.0948, found: 298.0951;  $[\alpha]_D^{25} = +6.3$  (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 13.716 min (minor), 42.619 min (major).



(*S*)-*N*-Methyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (15): Following the general procedure **A**, compound **15** was obtained as a white solid in 96% yield (22.3 mg), 82% ee;  $R_f = 0.3$  (petroleum ether/ethyl acetate = 4/1); m.p: 120 – 122 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.48 (brs, 1H), 7.32 – 7.24 (m, 2H), 7.22 – 7.18 (m 1H), 7.15 – 7.09 (m, 1H), 5.88 (ddd, *J* = 16.7, 9.9, 6.4 Hz, 1H), 5.05 (d, *J* = 10.0 Hz, 1H), 5.00 (d, *J* = 16.9 Hz, 1H), 4.94 (d, *J* = 6.4 Hz, 1H), 3.22 (d, *J* = 5.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.9, 148.2, 137.4, 129.8, 128.5, 125.9, 123.4, 116.2, 115.3, 107.2, 39.6, 27.9. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub>: 232.0842, found: 232.0845; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +19.3 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak IC, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 28.767 min (major), 36.700 min (minor).



(*S*)-*N*-Ethyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (16): Following the general procedure A, compound 16 was obtained as a yellow solid in 98% yield (24.1 mg), 65% ee;  $R_f = 0.3$  (petroleum ether/ethyl acetate = 4/1); m.p: 103 – 105 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.50 (brs, 1H), 7.30 – 7.25 (m, 2H), 7.21 (d, *J* = 7.1 Hz, 1H), 7.10 (d, *J* = 6.0 Hz, 1H), 5.88 (ddd, *J* = 16.9, 9.9, 6.1 Hz, 1H), 5.05 (d, *J* = 9.6 Hz, 1H), 4.99 (d, *J* = 16.6 Hz, 1H), 4.95 (d, *J* = 7.0 Hz, 1H), 3.71 – 3.59 (m, 2H), 1.38 (t, *J* = 7.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.3, 148.3, 137.4, 129.8, 128.5, 125.8, 123.5, 116.1, 115.3, 106.9, 39.6, 36.7, 15.2. HRMS (EI-TOF)

m/z: [M]<sup>+</sup> calcd for C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>: 246.0999, found: 246.1001;  $[\alpha]_D^{25} = +16.9$  (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); **HPLC** (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 8.319 min (minor), 36.278 min (major).



(*S*)-3-Nitro-*N*-propyl-4-vinyl-4*H*-chromen-2-amine (17): Following the general procedure A, compound 17 was obtained as a yellow solid in 95% yield (24.6 mg), 69% ee;  $R_f = 0.6$  (petroleum ether/ethyl acetate = 4/1); m.p: 82 – 84 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.59 (brs, 1H), 7.26 (d, *J* = 6.8 Hz, 2H), 7.21 (d, *J* = 7.4 Hz, 1H), 7.11 (d, *J* = 8.1 Hz, 1H), 5.92 – 5.84 (m, 1H), 5.05 (d, *J* = 10.0 Hz, 1H), 5.00 (d, *J* = 17.0 Hz, 1H), 4.95 (d, *J* = 6.3 Hz, 1H), 3.58 (t, *J* = 6.3 Hz, 2H), 1.80 – 1.71 (m, 2H), 1.05 (t, *J* = 7.5 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.4, 148.2, 137.3, 129.7, 128.4, 125.8, 123.4, 116.1, 115.3, 106.9, 43.3, 39.6, 23.1, 11.5. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>: 260.1155, found: 260.1159; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +5.4 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 7.287 min (minor), 18.508 min (major).



(*S*)-*N*-Butyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (18): Following the general procedure A, compound 18 was obtained as a yellow solid in 90% yield (24.6 mg), 75% ee;  $R_f = 0.3$  (petroleum ether/ethyl acetate = 4/1); m.p: 77 – 79 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.57 (brs, 1H), 7.30 – 7.26 (m, 2H), 7.22 – 7.18 (m, 1H), 7.10 (dd, *J* = 8.2, 1.3 Hz, 1H), 5.88 (ddd, *J* = 16.7, 10.0, 6.4 Hz, 1H), 5.05 (d, *J* = 10.0 Hz, 1H), 5.00 (d, *J* = 16.9 Hz, 1H), 4.95 (d, *J* = 6.6 Hz, 1H), 3.65 – 3.57 (m, 2H), 1.77 – 1.65 (m, 2H), 1.54 – 1.40 (m, 2H), 0.99 (t, *J* = 7.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.4, 148.3, 137.4, 129. 8, 128.5, 125.8, 123.5, 116.1, 115.3, 107.0, 41.4, 39.6, 31.8, 20.1, 13.8. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>: 274.1312, found: 274.1315; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +13.5 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 6.707 min (minor), 13.253 min (major).



(S)-N-Isopropyl-3-nitro-4-vinyl-4H-chromen-2-amine (19): Following the general procedure A, compound 19 was obtained as a yellow solid in 88% yield (22.9 mg), 72% ee;  $R_f$ 

= 0.3 (petroleum ether/ethyl acetate = 4/1); m.p: 134 – 136 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.46 (brs, 1H), 7.31 – 7.26 (m, 2H), 7.20 (d, J = 7.9 Hz, 1H), 7.11 (d, J = 8.6 Hz, 1H), 5.88 (ddd, J = 16.7, 10.0, 6.4 Hz, 1H), 5.05 (d, J = 10.0 Hz, 1H), 4.99 (d, J = 17.0 Hz, 2H), 4.95 (d, J = 6.3 Hz, 1H), 4.38 – 4.22 (m, 1H), 1.41 (d, J = 6.6 Hz, 3H), 1.38 (d, J = 6.5 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 158.6, 148.3, 137.4, 129.7, 128.4, 125.8, 123.5, 116.1, 115.3, 106.8, 44.5, 39.6, 23.4, 23.2. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>: 260.1155, found: 260.1158; [α]<sub>D</sub><sup>25</sup> = +14.1 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 5.879 min (minor), 20.802 min (major).



(*R*)-*N*-(2,2-Difluoroethyl)-4-vinyl-4*H*-chromen-2-amine (20): Following the general procedure **A**, compound **20** was obtained as a white solid in 98% yield (27.6 mg), 83% ee; R<sub>f</sub> = 0.4 (petroleum ether/ethyl acetate = 4/1); m.p: 134 – 136 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.40 (brs, 1H), 7.34 – 7.18 (m, 3H), 7.11 (dd, *J* = 8.1, 1.3 Hz, 1H), 6.02 (tt, *J*<sub>*H*-*F*</sub> = 55.2 Hz, *J* = 3.8 Hz, 1H), 5.85 (ddd, *J* = 16.8, 10.0, 6.8 Hz, 1H), 5.07 (d, *J* = 10.0 Hz, 1H), 5.03 (d, *J* = 17.0 Hz, 1H), 4.92 (d, *J* = 6.6 Hz, 1H), 3.98 (td, *J*<sub>*H*-*F*</sub> = 14.5 Hz, *J* = 6.6 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.1, 147.9, 137.2, 129.8, 128.6, 126.2, 123.3, 116.1, 115.7, 113.2(t, <sup>1</sup>*J*<sub>*C*-*F*</sup> = 242.0 Hz), 108.2, 43.4(t, <sup>2</sup>*J*<sub>*C*-*F*</sub> = 26.8 Hz), 39.5. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -122.59 (dtd, *J* = 55.4, 14.4, 7.0 Hz). HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>13</sub>H<sub>12</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub>: 282.0811, found: 282.0811; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +12.9 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 10.387 min (minor), 49.030 min (major).</sub>



(*S*)-*N*-(3-Chloropropyl)-3-nitro-4-vinyl-4*H*-chromen-2-amine (21): Following the general procedure **A**, compound **21** was obtained as a yellow solid in 62% yield (18.3 mg), 77% ee;  $R_f = 0.3$  (petroleum ether/ethyl acetate = 4/1); m.p: 94 – 96 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.54 (brs, 1H), 7.33 – 7.26 (m, 2H), 7.24 – 7.19 (m, 1H), 7.14 (dd, *J* = 8.1, 1.3 Hz, 1H), 5.87 (ddd, *J* = 16.8, 10.0, 6.5 Hz, 1H), 5.06 (d, *J* = 10.0 Hz, 1H), 5.01 (d, *J* = 17.0 Hz, 1H), 4.94 (d, *J* = 6.5 Hz, 1H), 3.88 – 3.75 (m, 2H), 3.67 (t, *J* = 6.0 Hz, 2H), 2.23 – 2.16 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.4, 148.1, 137.3, 129.7, 128.5, 125.9, 123.3, 116.2, 115.5, 107.3, 41.8, 39.6, 38.7, 32.5. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>14</sub>H<sub>15</sub><sup>35</sup>ClN<sub>2</sub>O<sub>3</sub>: 294.0766, found: 294.0766; C<sub>14</sub>H<sub>15</sub><sup>37</sup>ClN<sub>2</sub>O<sub>3</sub>: 296.0737, found: 296.0748; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +18.5 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 12.271 min (minor), 28.732 min (major).



(*S*)-*N*-Cyclopropyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (22): Following the general procedure **A**, compound **22** was obtained as a yellow solid in 93% yield (24.1 mg), 60% ee;  $R_f = 0.6$  (petroleum ether/ethyl acetate = 4/1); m.p: 128 – 130 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.35 (brs, 1H), 7.35 – 7.23 (m, 2H), 7.21 (d, *J* = 7.4 Hz, 1H), 7.15 (d, *J* = 8.1 Hz, 1H), 5.91 – 5.83 (m, 1H), 5.05 (d, *J* = 10.0 Hz, 1H), 5.00 (d, *J* = 17.0 Hz, 1H), 4.93 (d, *J* = 6.4 Hz, 1H), 3.03 (tt, *J* = 7.8, 3.9 Hz, 1H), 0.95 – 1.00 (m, 2H), 0.87 – 0.74 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.88, 148.28, 137.34, 129.72, 128.48, 125.83, 123.33, 116.33, 115.42, 107.37, 39.55, 23.94, 7.41(2C). HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>14</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>: 258.0999, found: 258.1007; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +2.4 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 7.778 min (minor), 27.845 min (major).



(*S*)-*N*-Cyclobutyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (23): Following the general procedure **A**, compound **23** was obtained as a yellow solid in 93% yield (25.3 mg), 70% ee; R<sub>f</sub> = 0.3 (petroleum ether/ethyl acetate = 4/1); m.p: 131 – 133 °C; <sup>1</sup>**H** NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.56 (brs, 1H), 7.30 – 7.24 (m, 2H), 7.21 – 7.17 (m, 1H), 7.08 (dd, *J* = 8.0, 1.2 Hz, 1H), 5.87 (ddd, *J* = 16.7, 10.0, 6.4 Hz, 1H), 5.05 (d, *J* = 9.9 Hz, 1H), 4.99 (d, *J* = 16.9 Hz, 1H), 4.93 (d, *J* = 6.4 Hz, 1H), 4.56 – 4.46 (m, 1H), 2.52 – 2.45 (m, 2H), 2.27 – 2.09 (m, 2H), 1.97 – 1.79 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.2, 148.2, 137.4, 129.7, 128.4, 125.8, 123.4, 116.1, 115.3, 106.9, 46.6, 39.5, 31.5, 31.3, 15.5. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>15</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>: 272.1155, found: 272.1157; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +10.0 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 7.547 min (minor), 19.735 min (major).



(*S*)-*N*-Cyclopentyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (24): Following the general procedure **A**, compound 24 was obtained as a yellow solid in 91% yield (26.0 mg), 69% ee;  $R_f = 0.3$  (petroleum ether/ethyl acetate = 4/1); m.p: 93 – 95 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.59 (brs, 1H), 7.30 – 7.25 (m, 2H), 7.22 – 7.17 (m, 1H), 7.11 (dd, *J* = 8.1, 1.3 Hz, 1H), 5.88 (ddd, *J* = 16.7, 10.0, 6.4 Hz, 1H), 5.05 (d, *J* = 9.9 Hz, 1H), 4.99 (d, *J* = 16.9 Hz, 1H), 4.94 (d, *J* = 6.3 Hz, 1H), 4.43 – 4.35 (m, 1H), 2.22 – 2.07 (m, 2H), 1.90 – 1.79 (m, 2H), 1.78 – 1.67 (m,

4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.9, 148.3, 137.4, 129.8, 128.4, 125. 8, 123.5, 116.1, 115.3, 106.9, 53.6, 39.6, 34.0, 33. 8, 23.9, 23.9. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>16</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>: 286.1312, found: 286.1314; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +10.9 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 6.577 min (minor), 16.542 min (major).



(*S*)-6-Fluoro-3-nitro-*N*-phenyl-4-vinyl-4*H*-chromen-2-amine (25): Following the general procedure **A**, compound **25** was obtained as a yellow solid in 98% yield (30.6 mg), 87% ee; R<sub>f</sub> = 0.6 (CH<sub>2</sub>Cl<sub>2</sub>); m.p: 138 – 140 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 12.18 (brs, 1H), 7.47 – 7.40 (m, 4H), 7.32 – 7.29 (m, 1H), 7.05 (dd, J = 8.7, 4.5 Hz, 1H), 6.99 (d, J = 8.1 Hz, 2H), 5.90 (ddd, J = 16.6, 9.9, 6.6 Hz, 1H), 5.14 (d, J = 9.2 Hz, 1H), 5.10 (d, J = 15.6 Hz, 1H), 4.99 (d, J = 6.7 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 160.0 (d, <sup>1</sup> $J_{C-F} = 245.6$  Hz), 156.7, 144.2, 136.6, 135.1, 129.6 (2C), 126.8, 125.3 (d, <sup>3</sup> $J_{C-F} = 7.9$  Hz), 123.4 (2C), 117.8 (d, <sup>3</sup> $J_{C-F} = 8.4$  Hz), 116.4, 115.9 (d, <sup>2</sup> $J_{C-F} = 23.9$  Hz), 115.7 (d, <sup>2</sup> $J_{C-F} = 24.1$  Hz), 107.6, 39.9. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ - 115.76 – -115.82 (m). HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub>FN<sub>2</sub>O<sub>3</sub>: 312.0905, found: 312.0909; [α]<sub>D</sub><sup>25</sup> = +23.8 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 8.241 min (minor), 13.449 min (major).



(*S*)-6-Fluoro-*N*-methyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (26): Following the general procedure **A**, compound 26 was obtained as a yellow solid in 98% yield (24.5mg), 88% ee; R<sub>f</sub> = 0.4 (petroleum ether/ethyl acetate = 4/1); m.p: 139 – 141 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.42 (brs, 1H), 7.11 (dd, *J* = 8.7, 4.5 Hz, 1H), 7.03 – 6.93 (m, 2H), 5.85 (ddd, *J* = 16.7, 10.0, 6.6 Hz, 1H), 5.09 (d, *J* = 10.0 Hz, 1H), 5.04 (d, *J* = 16.9 Hz, 1H), 4.91 (d, *J* = 6.5 Hz, 1H), 3.22 (d, *J* = 5.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.4 (d, <sup>1</sup>*J* <sub>*C-F*</sub> = 140.8 Hz), 158.6, 144.3, 136.8, 125.3 (d, <sup>3</sup>*J* <sub>*C-F*</sub> = 8.0 Hz), 117.7 (d, <sup>3</sup>*J* <sub>*C-F*</sub> = 8.7 Hz), 115.9 (d, <sup>2</sup>*J* <sub>*C-F*</sub> = 12.7 Hz), 115.7 (d, <sup>2</sup>*J* <sub>*C-F*</sub> = 15.7 Hz), 115.4, 106.6, 39.9, 28.0. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -116.21 – -116.24(m). HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>12</sub>H<sub>11</sub>FN<sub>2</sub>O<sub>3</sub>: 250.0748, found: 250.0752; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +16.9 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 11.028 min (minor), 55.533 min (major).



(*S*)-6-Fluoro-*N*-isopropyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (27): Following the general procedure **A**, compound **27** was obtained as a yellow solid in 90% yield (25.0mg), 79% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 140 – 142 °C; <sup>1</sup>**H** NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.39 (brs, 1H), 7.09 (dd, J = 8.6, 4.5 Hz, 1H), 7.01 – 6.95 (m, 2H), 5.86 (ddd, J = 16.8, 10.0, 6.5 Hz, 1H), 5.09 (d, J = 10.0 Hz, 1H), 5.03 (d, J = 16.9 Hz, 1H), 4.92 (d, J = 6.6 Hz, 1H), 4.32 – 4.24 (m, 1H), 1.40 (d, J = 6.5 Hz, 3H), 1.37 (d, J = 6.5 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.8 (d, <sup>1</sup> $J_{C-F} = 245.2$  Hz), 158.4, 144.3 (d, <sup>4</sup> $J_{C-F} = 2.6$  Hz), 136.8, 125.4 (d, <sup>3</sup> $J_{C-F} = 8.0$  Hz), 117.5 (d, <sup>3</sup> $J_{C-F} = 8.6$  Hz), 115.9 (d, <sup>2</sup> $J_{C-F} = 17.5$  Hz), 115.8, 115.5 (d, <sup>2</sup> $J_{C-F} = 24.1$  Hz), 106.2, 44.5, 39.8, 23.4, 23.2. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -116.29 – -116.40 (m). **HRMS** (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>14</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>3</sub>: 278.1061, found: 278.1064; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +10.6 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); **HPLC** (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 5.905 min (minor), 17.752 min (major).



(*S*)-6-Chloro-3-nitro-*N*-phenyl-4-vinyl-4*H*-chromen-2-amine (28): Following the general procedure **A**, compound **28** was obtained as a yellow solid in 98% yield (32.1mg), 96% ee;  $R_f = 0.5 (CH_2Cl_2)$ ; m.p: 146 – 148 °C; <sup>1</sup>H NMR (400 MHz, CDCl\_3)  $\delta$  12.18 (brs, 1H), 7.47 – 7.39 (m, 4H), 7.31 (d, *J* = 7.2 Hz, 1H), 7.28 – 7.22 (m, 2H), 7.02 (d, *J* = 8.5 Hz, 1H), 5.88 (ddd, *J* = 16.8, 10.0, 6.7 Hz, 1H), 5.14 (d, *J* = 10.0 Hz, 1H), 5.11 (d, *J* = 16.8 Hz, 1H), 4.97 (d, *J* = 6.7 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl\_3)  $\delta$  156.5, 146.6, 136.6, 134.9, 131.2, 129.6(2C), 129.4, 128.7, 126.8, 125.1, 123.4(2C), 117.7, 116.4, 107.7, 39.6. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>35</sup>ClN<sub>2</sub>O<sub>3</sub>: 328.0610, found: 328.0611; C<sub>17</sub>H<sub>13</sub><sup>37</sup>ClN<sub>2</sub>O<sub>3</sub>: 330.0580, found: 328.0589; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +23.9 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 8.652 min (minor), 11.454 min (major).



(*S*)-6-Chloro-*N*-methyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (29): Following the general procedure A, compound 29 was obtained as a yellow solid in 99% yield (26.3mg), 86% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 156 – 158 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.41 (brs, 1H), 7.29 – 7.22 (m, 2H), 7.11 – 7.04 (m, 1H), 5.83 (ddd, *J* = 16.8, 10.0, 6.6 Hz, 1H), 5.09 (d, *J* = 10.0 Hz, 1H), 5.04 (d, *J* = 16.9 Hz, 1H), 4.89 (d, *J* = 6.6 Hz, 1H), 3.22 (d, *J* =

5.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.5, 146.7, 136.8, 130.9, 129. 5, 128.6, 125.2, 117.6, 116.0, 106.7, 39.6, 28.1. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>12</sub>H<sub>11</sub><sup>35</sup>ClN<sub>2</sub>O<sub>3</sub>: 266.0453, found: 266.0457; C<sub>12</sub>H<sub>11</sub><sup>37</sup>ClN<sub>2</sub>O<sub>3</sub>: 268.0424, found: 268.0427; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +27.6 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 10.521 min (minor), 21.262 min (major).



(*S*)-6-Chloro-*N*-isopropyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (30): Following the general procedure **A**, compound **30** was obtained as a yellow solid in 85% yield (24.9mg), 90% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 153 – 155 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.37 (brs, 1H), 7.25 (d, *J* = 7.6 Hz, 2H), 7.10 – 7.03 (m, 1H), 5.84 (ddd, *J* = 16.8, 10.0, 6.6 Hz, 1H), 5.08 (d, *J* = 9.9 Hz, 1H), 5.04 (d, *J* = 16.9 Hz, 1H), 4.89 (d, *J* = 6.7 Hz, 1H), 4.33 – 4.24 (m, 1H), 1.40 (d, *J* = 6.6 Hz, 3H), 1.38 (d, *J* = 6.5 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.2, 146.7, 136.7, 130.8, 129.3, 128.5, 125.2, 117.5, 115.9, 106.2, 44.5, 39.5, 23.3, 23.2. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>14</sub>H<sub>15</sub><sup>35</sup>ClN<sub>2</sub>O<sub>3</sub>: 294.0766, found: 294.0774; C<sub>14</sub>H<sub>15</sub><sup>37</sup>ClN<sub>2</sub>O<sub>3</sub>: 296.0737, found: 294.0743; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = -0.1 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 6.428 min (minor), 16.698 min (major).



(*S*)-6-Bromo-3-nitro-*N*-phenyl-4-vinyl-4*H*-chromen-2-amine (31): Following the general procedure **A**, compound **31** was obtained as a yellow solid in 99% yield (36.8mg), 95% ee;  $R_f = 0.6 (CH_2Cl_2)$ ; m.p: 135 – 137 °C; <sup>1</sup>H NMR (400 MHz, CDCl\_3)  $\delta$  12.18 (brs, 1H), 7.52 – 7.35 (m, 6H), 7.35 – 7.26 (m, 1H), 6.96 (d, *J* = 8.7 Hz, 1H), 5.88 (ddd, *J* = 16.8, 10.0, 6.7 Hz, 1H), 5.14 (d, *J* = 7.2 Hz, 1H), 5.11 (d, *J* = 14.1 Hz, 1H), 4.97 (d, *J* = 6.8 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl\_3)  $\delta$  156.5, 147.1, 136.6, 134.9, 132.4, 131.6, 129.6(2C), 126.8, 125.5, 123.4(2C), 118.7, 118.1, 116.5, 107.7, 39.5. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>79</sup>BrN<sub>2</sub>O<sub>3</sub>: 372.0105, found: 372.0112; C<sub>17</sub>H<sub>13</sub><sup>81</sup>BrN<sub>2</sub>O<sub>3</sub>: 374.0084, found: 374.0085; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +18.2 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 8.859 min (minor), 11.241 min (major).



(*S*)-6-Bromo-*N*-methyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (32): Following the general procedure **A**, compound **32** was obtained as a yellow solid in 98% yield (30.3mg), 78% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 188 – 190 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.41 (brs, 1H), 7.43 – 7.36 (m, 2H), 7.06 – 6.99 (m, 1H), 5.83 (ddd, J = 16.8, 9.9, 6.7 Hz, 1H), 5.09 (d, J = 10.0 Hz, 1H), 5.04 (d, J = 16.9 Hz, 1H), 4.88 (d, J = 6.7 Hz, 1H), 3.22 (d, J = 5.3 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.4, 147.2, 136.8, 132.4, 131.5, 125.6, 118.4, 117.9, 116.0, 106.6, 39.5, 28.1. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>12</sub>H<sub>11</sub><sup>79</sup>BrN<sub>2</sub>O<sub>3</sub>: 309.9948, found: 309.9957; C<sub>12</sub>H<sub>11</sub><sup>81</sup>BrN<sub>2</sub>O<sub>3</sub>: 311.9928, found: 311.9934; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +20.9 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 10.335 min (minor), 17.279 min (major).



(*S*)-6-Bromo-*N*-isopropyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (33): Following the general procedure **A**, compound **33** was obtained as a yellow solid in 88% yield (29.7mg), 84% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 144 – 146 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.38 (brs, 1H), 7.41 – 7.38 (m, 2H), 7.00 (d, J = 9.2 Hz, 1H), 5.84 (ddd, J = 16.8, 10.0, 6.6 Hz, 1H), 5.09 (d, J = 10.0 Hz, 1H), 5.04 (d, J = 17.0 Hz, 1H), 4.90 (d, J = 6.6 Hz, 1H), 4.33 – 4.20 (m, 1H), 1.40 (d, J = 6.6 Hz, 3H), 1.37 (d, J = 6.5 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.2, 147.4, 136.8, 132.4, 131.5, 125.8, 118.4, 117.9, 116.0, 106.3, 44.6, 39.5, 23.4, 23.3. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>14</sub>H<sub>15</sub><sup>79</sup>BrN<sub>2</sub>O<sub>3</sub>: 338.0261, found: 338.0265; C<sub>14</sub>H<sub>15</sub><sup>81</sup>BrN<sub>2</sub>O<sub>3</sub>: 340.0241, found: 340.0248; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +8.3 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 6.076 min (minor), 12.532 min (major).



(*S*)-6-Methyl-3-nitro-*N*-phenyl-4-vinyl-4*H*-chromen-2-amine (34): Following the general procedure **A**, compound **34** was obtained as a yellow solid in 98% yield (30.2 mg), 89% ee; R<sub>f</sub> = 0.5 (CH<sub>2</sub>Cl<sub>2</sub>); m.p: 168 – 170 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  12.31 (brs, 1H), 7.46 – 7.41 (m, 4H), 7.31 – 7.26 (m, 1H), 7.06 (dd, *J* = 5.7, 2.4 Hz, 2H), 6.96 (d, *J* = 8.9 Hz, 1H), 5.90 (ddd, *J* = 17.4, 9.5, 6.6 Hz, 1H), 5.11 (d, *J* = 10 Hz, 1H), 5.07 (d, *J* = 16.8 Hz, 1H), 4.95 (d, *J* = 6.6 Hz, 1H), 2.34 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  157.0, 146.0, 137.2, 135.9, 135.2, 129.8, 129.5(2C), 129.2, 126.5, 123.2(2C), 122.9, 115.9, 115.7, 108.2, 39.6, 20.9. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>: 308.1155, found: 308.1158; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +22.1 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 8.094 min (minor), 14.282 min (major).



(*S*)-*N*,6-Dimethyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (35): Following the general procedure **A**, compound **35** was obtained as a yellow solid in 98% yield (24.1mg), 64% ee; R<sub>f</sub> = 0.4 (petroleum ether/ethyl acetate = 4/1); m.p: 151 – 153 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.49 (brs, 1H), 7.14 – 6.95 (m, 3H), 5.85 (ddd, *J* = 16.8, 10.0, 6.6 Hz, 1H), 5.04 (d, *J* = 10.0 Hz, 1H), 5.01 (d, *J* = 16.4 Hz, 1H), 4.87 (d, *J* = 6.7 Hz, 1H), 3.21 (d, *J* = 5.2 Hz, 3H), 2.34 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.0, 146.1, 137.4, 135.6, 129.8, 129.0, 122.9, 115.9, 115.2, 107.2, 39.6, 27.9, 20.8. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>: 246.0999, found: 246.1006; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +22.6 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 9.497 min (minor), 29.834 min (major).



(*S*)-*N*-Isopropyl-6-methyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (36): Following the general procedure **A**, compound **36** was obtained as a yellow solid in 82% yield (22.5mg), 65% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 104 – 106 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.48 (brs, 1H), 7.06 (d, *J* = 8.1 Hz, 1H), 7.04 (s, 1H), 6.99 (d, *J* = 8.2 Hz, 1H), 5.86 (ddd, *J* = 16.7, 10.0, 6.5 Hz, 1H), 5.05 (d, *J* = 8.8 Hz, 1H), 5.01 (d, *J* = 15.8 Hz, 1H), 4.89 (d, *J* = 6.4 Hz, 1H), 4.32 – 4.24 (m, 1H), 2.34 (s, 3H), 1.39 (d, *J* = 6.6 Hz, 3H), 1.37 (d, *J* = 6.5 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.8, 146.3, 137.4, 135.6, 129.9, 129.0, 123.1, 115.8, 115.2, 106.9, 44.4, 39.7, 23.4, 23.2, 20.9. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>: 274.1312, found: 274.1320; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +15.8 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 5.824 min (minor), 22.793 min (major).



(*S*)-6-Methoxy-3-nitro-*N*-phenyl-4-vinyl-4*H*-chromen-2-amine (37): Following the general procedure **A**, compound **37** was obtained as a yellow solid in 97% yield (31.4 mg), 99% ee;  $R_f = 0.5 (CH_2Cl_2)$ ; m.p: 155 – 157 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  12.29 (brs, 1H), 7.49 – 7.38 (m, 4H), 7.33 – 7.27 (m, 1H), 7.01 (d, *J* = 8.9 Hz, 1H), 6.84 – 6.73 (m, 2H), 5.91 (ddd, *J* = 16.7, 9.7, 6.6 Hz, 1H), 5.12 (d, *J* = 9.6 Hz, 1H), 5.09 (d, *J* = 17.2 Hz, 1H), 4.98 (d, *J* = 6.6 Hz, 1H), 3.81 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  157.4, 157.0, 142.1, 136.9, 135.2, 129.5(2C), 126.5, 124.2, 123.2(2C), 117.2, 115.9, 114.5, 113.5, 107.9, 55.9, 40.0. HRMS (EI-TOF) m/z:

[M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub>: 324.1105, found: 324.1113;  $[\alpha]_D^{25} = +14.5$  (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); **HPLC** (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 12.304 min (minor), 19.211 min (major).



(*S*)-6-Methoxy-*N*-methyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (38): Following the general procedure **A**, compound **38** was obtained as a yellow solid in 80% yield (20.9mg), 52% ee; R<sub>f</sub> = 0.4 (petroleum ether/ethyl acetate = 4/1); m.p: 155 – 157 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.47 (brs, 1H), 7.05 (d, *J* = 8.9 Hz, 1H), 6.81 (d, *J* = 9.1 Hz, 1H), 6.73 (s, 1H), 5.86 (ddd, *J* = 15.8, 8.7, 6.6 Hz, 1H), 5.06 (d, *J* = 8.0 Hz, 1H), 5.03 (d, *J* = 15.3 Hz, 1H), 4.89 (d, *J* = 6.6 Hz, 1H), 3.80 (s, 3H), 3.20 (d, *J* = 5.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.0, 157.2, 142.2, 137.2, 124.3, 117.1, 115.4, 114.4, 113.5, 106.9, 55.8, 39.9, 27.9. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>: 262.0948, found: 262.0951; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +15.7 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak IC-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 35.147 min (major), 47.328 min (minor).



(*S*)-*N*-Isopropyl-6-methoxy-3-nitro-4-vinyl-4*H*-chromen-2-amine (39): Following the general procedure **A**, compound **39** was obtained as a yellow solid in 86% yield (24.9mg), 41% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 103 – 105 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.45 (brs, 1H), 7.03 (d, *J* = 8.9 Hz, 1H), 6.81 (dd, *J* = 8.9, 3.0 Hz, 1H), 6.74 (d, *J* = 3.0 Hz, 1H), 5.87 (ddd, *J* = 16.5, 10.3, 6.2 Hz, 1H)., 5.06 (d, *J* = 8.8 Hz, 1H), 5.03 (d, *J* = 14.6 Hz, 1H), 4.90 (d, *J* = 6.4 Hz, 1H), 4.32 – 4.23 (m, 1H), 3.80 (s, 3H), 1.39 (d, *J* = 6.6 Hz, 3H), 1.37 (d, *J* = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.8, 157.1, 142.3, 137.1, 124.4, 116.9, 115.4, 114.4, 113.5, 106.6, 55.8, 44.4, 39.9, 23.3, 23.2. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub>: 290.1261, found: 290.1265; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +4.8 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 7.312 min (minor), 26.847 min (major).



(S)-3-Nitro-N-phenyl-6-(trifluoromethoxy)-4-vinyl-4H-chromen-2-amine (40): Following the general procedure A, compound 40 was obtained as a yellow solid in 97% yield (36.7mg),

90% ee;  $R_f = 0.6 (CH_2Cl_2)$ ; m.p: 96 – 98 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  12.16 (brs, 1H), 7.48 – 7.44 (m, 2H), 7.43 – 7.38 (m, 2H), 7.34 – 7.29 (m, 1H), 7.17 – 7.09 (m, 3H), 5.90 (ddd, J = 16.8, 10.0, 6.7 Hz, 1H), 5.15 (d, J = 10.0 Hz, 1H), 5.11 (d, J = 16.9 Hz, 1H), 5.02 (d, J = 6.6 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  156.5, 146.5, 146.3 136.5, 134.9, 129.6(2C), 126.9, 125.2, 123.5(2C), 122.2, 121.5, 120.5 (q, <sup>1</sup> $J_{C-F} = 256.5$  Hz), 117.8, 116.5, 107.5, 39.7. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -58.23(s). HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>13</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub>: 378.0822, found: 378.0824; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +16.2 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 5.547 min (minor), 7.354 min (major).



(*S*)-*N*-Methyl-3-nitro-6-(trifluoromethoxy)-4-vinyl-4*H*-chromen-2-amine (41): Following the general procedure **A**, compound **41** was obtained as a yellow solid in 98% yield (30.9mg), 77% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 133 – 135 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.40 (brs, 1H), 7.19 – 7.16 (m, 2H), 7.13 (s), 5.85 (ddd, *J* = 16.7, 10.0, 6.5 Hz, 1H), 5.10 (d, *J* = 9.9 Hz, 1H), 5.03 (d, *J* = 16.9 Hz, 1H), 4.93 (d, *J* = 6.6 Hz, 1H), 3.23 (d, *J* = 5.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.5, 146.4, 146.3, 136.7, 125.3, 122.2, 121.3, 120.5 (q, <sup>1</sup>*J* <sub>*C-F*</sub> = 256.3 Hz), 117.7, 116.0, 106.5, 39.7, 28.1. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -58.25(s). HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>13</sub>H<sub>11</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub>: 316.0665, found: 316.0673; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +16.1 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 7.580 min (minor), 10.998 min (major).



(*S*)-*N*-Isopropyl-3-nitro-6-(trifluoromethoxy)-4-vinyl-4*H*-chromen-2-amine (42): Following the general procedure **A**, compound **42** was obtained as a yellow solid in 92% yield (31.6mg), 84% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 77 – 79 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.37 (brs, 1H), 7.17 – 7.12 (m, 3H), 5.86 (ddd, *J* = 16.8, 10.0, 6.4 Hz, 1H), 5.10 (d, *J* = 9.7 Hz, 1H), 5.03 (d, *J* = 16.8 Hz, 1H), 4.95 (d, *J* = 6.7 Hz, 1H), 4.32 – 4.24 (m, 1H), 1.41 (d, *J* = 6.2 Hz, 3H), 1.38 (d, *J* = 6.6 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ 158.3, 146.5, 146.3, 136.7, 125.4, 122.3, 121.4, 120.5 (q, <sup>1</sup>*J C*-*F* = 247.2 Hz), 117.5, 116.1, 106.1, 44.6, 39.8, 23.4, 23.3. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -58.25(s). HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>15</sub>H<sub>15</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub>: 344.0978, found: 344.0986; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +10.9 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 4.586 min (minor), 8.490 min (major).



(*S*)-7-Bromo-3-nitro-*N*-phenyl-4-vinyl-4*H*-chromen-2-amine (43): Following the general procedure **A**, compound 43 was obtained as a yellow solid in 99% yield (36.8mg), 95% ee; R<sub>f</sub> = 0.6 (CH<sub>2</sub>Cl<sub>2</sub>); m.p: 154 – 156 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 12.16 (brs, 1H), 7.48 – 7.44 (m, 2H), 7.39 (d, *J* = 7.9 Hz, 2H), 7.37 – 7.29 (m, 2H), 7.24 (s), 7.16 (d, *J* = 8.2 Hz, 1H), 5.89 (ddd, *J* = 16.8, 10.0, 6.6 Hz, 1H), 5.12 (d, *J* = 10.0 Hz, 1H), 5.07 (d, *J* = 16.9 Hz, 1H), 4.97 (d, *J* = 6.6 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 156.5, 148.4, 136.8, 134.9, 130.9, 129.6(2C), 129.3, 126.9, 123.5(2C), 122.5, 121.3, 119.6, 116.2, 107.9, 39.29. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>79</sup>BrN<sub>2</sub>O<sub>3</sub>: 372.0105, found: 372.0115; C<sub>17</sub>H<sub>13</sub><sup>81</sup>BrN<sub>2</sub>O<sub>3</sub>: 374.0084, found: 374.0085; [α]<sub>D</sub><sup>25</sup> = +12.8 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 8.658 min (minor), 12.162 min (major).



(*S*)-7-Bromo-*N*-methyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (44): Following the general procedure **A**, compound 44 was obtained as a yellow solid in 97% yield (29.9mg), 74% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 126 – 128 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.41 (brs, 1H), 7.34 – 7.32 (m, 2H), 7.14 (d, *J* = 8.5 Hz, 1H), 5.84 (ddd, *J* = 16.7, 10.0, 6.5 Hz, 1H), 5.06 (d, *J* = 10.0 Hz, 1H), 5.00 (d, *J* = 17.0 Hz, 1H), 4.88 (d, *J* = 6.4 Hz, 1H), 3.22 (d, *J* = 5.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.4, 148.4, 136.9, 130.9, 128.9, 122.5, 121.1, 119.5, 115.8, 106.8, 39.2, 28.1. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>12</sub>H<sub>11</sub><sup>79</sup>BrN<sub>2</sub>O<sub>3</sub>: 309.9948, found: 309.9952; C<sub>12</sub>H<sub>11</sub><sup>81</sup>BrN<sub>2</sub>O<sub>3</sub>: 311.9928, found: 311.9934; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +9.8 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 12.740 min (minor), 34.731 min (major).



(*S*)-7-Bromo-*N*-isopropyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (45): Following the general procedure **A**, compound 45 was obtained as a yellow solid in 92% yield (31.1mg), 64% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 156 – 158 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.38 (brs, 1H), 7.35 – 7.29 (m, 2H), 7.14 (d, *J* = 8.2 Hz, 1H), 5.85 (ddd, *J* = 16.7, 10.0, 6.4 Hz, 1H), 5.07 (d, *J* = 10.0 Hz, 1H), 5.00 (d, *J* = 16.9 Hz, 1H), 4.90 (d, *J* = 6.4 Hz, 1H), 4.35 – 4.18 (m, 1H), 1.40 (d, *J* = 6.6 Hz, 3H), 1.37 (d, *J* = 6.5 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.2, 148.6, 136.9, 131.0, 128.9, 122.7, 121.2, 119.5, 115.8, 106.5, 44.6, 39.3, 23.4, 23.3.

**HRMS** (EI-TOF) m/z:  $[M]^+$  calcd for  $C_{14}H_{15}^{79}BrN_2O_3$ : 338.0261, found: 338.0262;  $C_{14}H_{15}^{81}BrN_2O_3$ : 340.0241, found: 340.0249;  $[\alpha]_D^{25} = +5.0$  (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); **HPLC** (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 6.125 min (minor), 13.359 min (major).



(*S*)-7-Chloro-3-nitro-*N*-phenyl-4-vinyl-4*H*-chromen-2-amine (46): Following the general procedure **A**, compound 46 was obtained as a yellow solid in 96% yield (31.6mg), 88% ee;  $R_f = 0.6 (CH_2Cl_2)$ ; m.p: 163 – 165 °C; <sup>1</sup>H NMR (400 MHz, CDCl\_3)  $\delta$  12.16 (brs, 1H), 7.48 – 7.44 (m, 2H), 7.39 (d, *J* = 7.8 Hz, 2H), 7.33 – 7.30 (m, 1H), 7.24 – 7.19 (m, 2H), 7.09 (d, *J* = 1.9 Hz, 1H), 5.89 (ddd, *J* = 16.7, 10.0, 6.6 Hz, 1H), 5.12 (d, *J* = 9.8 Hz, 1H), 5.07 (d, *J* = 17.2 Hz, 1H), 4.98 (d, *J* = 6.6 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl\_3)  $\delta$  156.5, 148.3, 136.9, 134.9, 133.9, 130.7, 129.6(2C), 126.9, 126.4, 123.5(2C), 121.9, 116.7, 116.2, 107.9, 39.2. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>35</sup>ClN<sub>2</sub>O<sub>3</sub>: 328.0610, found: 328.0612; C<sub>17</sub>H<sub>13</sub><sup>37</sup>ClN<sub>2</sub>O<sub>3</sub>: 330.0580, found: 328.0583; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +21.6 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 8.275 min (minor), 11.256 min (major).



(*S*)-7-Chloro-*N*-methyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (47): Following the general procedure **A**, compound **47** was obtained as a yellow solid in 87% yield (23.1mg), 89% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 138 – 140 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.42 (brs, 1H), 7.19 (d, *J* = 1.6 Hz, 2H), 7.17 (s, 1H), 5.84 (ddd, *J* = 16.7, 10.0, 6.5 Hz, 1H), 5.07 (d, *J* = 10.0 Hz, 1H), 5.00 (d, *J* = 16.9 Hz, 1H), 4.90 (d, *J* = 6.6 Hz, 1H), 3.22 (d, *J* = 5.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.4, 148.4, 137.0, 133.7, 130.7, 126.1, 122.0, 116.7, 115.8, 106.9, 39.2, 28.1. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>12</sub>H<sub>11</sub><sup>35</sup>ClN<sub>2</sub>O<sub>3</sub>: 266.0453, found: 266.0454; C<sub>12</sub>H<sub>11</sub><sup>37</sup>ClN<sub>2</sub>O<sub>3</sub>: 268.0424, found: 268.0430; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = -9.7 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 10.726 min (minor), 25.968 min (major).



(S)-7-Chloro-N-isopropyl-3-nitro-4-vinyl-4H-chromen-2-amine (48): Following the general procedure A, compound 48 was obtained as a yellow solid in 78% yield (22.9mg), 78% ee;  $R_f$ 

= 0.4 (petroleum ether/ethyl acetate = 4/1); m.p: 157 – 159 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.39 (brs, 1H), 7.22 – 7.19 (m, 2H), 7.15 (d, J = 1.7 Hz, 1H), 5.85 (ddd, J = 16.7, 10.0, 6.5 Hz, 1H), 5.07 (d, J = 10.0 Hz, 1H), 5.00 (d, J = 17.0 Hz, 1H), 4.91 (d, J = 6.4 Hz, 1H), 4.34 – 4.21 (m, 1H), 1.40 (d, J = 6.6 Hz, 3H), 1.38 (d, J = 6.5 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.2, 148.5, 136.9, 133.7, 130.7, 126.1, 122.1, 116.6, 115.7, 106.5, 44.6, 39.2, 23.4, 23.2. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>14</sub>H<sub>15</sub><sup>35</sup>ClN<sub>2</sub>O<sub>3</sub>: 294.0766, found: 294.0773; C<sub>14</sub>H<sub>15</sub><sup>37</sup>ClN<sub>2</sub>O<sub>3</sub>: 296.0737, found: 294.0739; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +33.3 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 6.020 min (minor), 12.457 min (major).



(*S*)-7-Chloro-*N*-cyclopropyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (49): Following the general procedure **A**, compound 49 was obtained as a yellow solid in 86% yield (25.1 mg), 69% ee;  $R_f = 0.3$  (petroleum ether/ethyl acetate = 4/1); m.p: 164 – 166 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.27 (brs, 1H), 7.21 – 7.17(m, 3H), 5.84 (ddd, *J* = 16.7, 10.0, 6.6 Hz, 1H), 5.07 (d, *J* = 10.0 Hz, 1H), 5.01 (d, *J* = 16.9 Hz, 1H), 4.89 (d, *J* = 6.6 Hz, 1H), 2.97 – 3.03 (m, 1H), 1.02 – 0.97 (m, 2H), 0.91 – 0.72 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160. 5, 148.5, 137.1, 133.8, 130.7, 126.1, 122.1, 116.8, 115.9, 107.2, 39.2, 24.0, 7.5, 7.5. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>14</sub>H<sub>13</sub><sup>35</sup>ClN<sub>2</sub>O<sub>3</sub>: 292.0610, found: 292.0611; C<sub>14</sub>H<sub>13</sub><sup>37</sup>ClN<sub>2</sub>O<sub>3</sub>: 294.0580, found: 294.0586; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +7.7 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 7.562 min (minor), 16.631 min (major).



(*S*)-7-Chloro-3-nitro-*N*-propyl-4-vinyl-4*H*-chromen-2-amine (50): Following the general procedure **A**, compound **50** was obtained as a yellow solid in 90% yield (25.1 mg), 58% ee;  $R_f = 0.3$  (petroleum ether/ethyl acetate = 4/1); m.p: 113 – 115 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.51 (brs, 1H), 7.19 (d, J = 2.4 Hz, 2H), 7.15 (s, 1H), 5.85 (ddd, J = 16.7, 9.9, 6.4 Hz, 1H), 5.07 (d, J = 10.0 Hz, 1H), 5.00 (d, J = 17.0 Hz, 1H), 4.91 (d, J = 6.4 Hz, 1H), 3.60 – 3.51 (m, 2H), 1.80 – 1.71 (m, 2H), 1.05 (t, J = 7.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.9, 148.4, 137.0, 133.7, 130.7, 126.1, 122.1, 116.6, 115.7, 106.7, 43.4, 39.2, 23.1, 11.5. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>14</sub>H<sub>15</sub><sup>35</sup>ClN<sub>2</sub>O<sub>3</sub>: 294.0766, found: 294.0768; C<sub>14</sub>H<sub>15</sub><sup>37</sup>ClN<sub>2</sub>O<sub>3</sub>: 296.0737; found: 296.0735, [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +10.7 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 7.017 min (minor), 12.371 min (major).



(*S*)-5-Chloro-3-nitro-*N*-phenyl-4-vinyl-4*H*-chromen-2-amine (51): Following the general procedure **A**, compound **51** was obtained as a yellow solid in 84% yield (27.7 mg), 99% ee;  $R_f = 0.6 (CH_2Cl_2)$ ; m.p: 146 – 148 °C; <sup>1</sup>H NMR (400 MHz, CDCl\_3)  $\delta$  12.09 (brs, 1H), 7.48 – 7.39 (m, 4H), 7.34 – 7.24 (m, 3H), 7.02 (d, *J* = 8.0 Hz, 1H), 5.98 (ddd, *J* = 16.6, 10.1, 5.9 Hz, 1H), 5.30 (d, *J* = 5.8 Hz, 1H), 5.15 (d, *J* = 10.0 Hz, 1H), 5.01 (d, *J* = 17.1 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl\_3)  $\delta$  156.8, 149.4, 135.0, 134.3, 134.1, 129.6(2C), 128.9, 127.0, 126.8, 123.4(2C), 122.7, 116.3, 115.0, 108.4, 37.4. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>35</sup>ClN<sub>2</sub>O<sub>3</sub>: 328.0610, found: 328.0620; C<sub>17</sub>H<sub>13</sub><sup>37</sup>ClN<sub>2</sub>O<sub>3</sub>: 330.0580, found: 330.0588; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +29.2 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 8.431 min (minor), 11.118 min (major).



(*S*)-5-Chloro-*N*-methyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (52): Following the general procedure **A**, compound **52** was obtained as a yellow solid in 92% yield (24.5mg), 92% ee;  $R_f = 0.3$  (petroleum ether/ethyl acetate = 4/1); m.p: 156 – 158 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.34 (brs, 1H), 7.30 – 7.24 (m, 2H), 7.08 (dd, *J* = 7.4, 1.9 Hz, 1H), 5.95 (ddd, *J* = 17.1, 10.0, 5.8 Hz, 1H), 5.22 (d, *J* = 5.8 Hz, 1H), 5.10 (d, *J* = 10.0 Hz, 1H), 4.93 (d, *J* = 17.1 Hz, 1H), 3.23 (d, *J* = 5.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.8, 149.4, 134.4, 134.1, 128.8, 126.8, 122.7, 115.8, 114.9, 107.3, 37.3, 28.1. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>12</sub>H<sub>11</sub><sup>35</sup>ClN<sub>2</sub>O<sub>3</sub>: 266.0453, found: 266.0461; C<sub>12</sub>H<sub>11</sub><sup>37</sup>ClN<sub>2</sub>O<sub>3</sub>: 268.0424, found: 268.0432; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +23.9 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 10.575 min (minor), 36.027 min (major).



(*S*)-5-Chloro-*N*-isopropyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (53): Following the general procedure **A**, compound **53** was obtained as a yellow solid in 74% yield (21.8mg), 57% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 100 – 102 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.30 (brs, 1H), 7.28 (d, *J* = 7.2 Hz, 1H), 7.23 (d, *J* = 8.0 Hz, 1H), 7.05 (dd, *J* = 7.8, 1.7 Hz, 1H), 5.95 (ddd, *J* = 16.6, 10.0, 5.8 Hz, 1H), 5.24 (d, *J* = 5.8 Hz, 1H), 5.10 (d, *J* = 10.0 Hz, 1H), 4.93 (d, *J* = 18.1 Hz, 1H), 4.32 – 4.24 (m, 1H), 1.41 (d, *J* = 6.6 Hz, 3H), 1.37 (d, *J* = 6.5 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.6, 149.6, 134.4, 134.2, 128.8, 126.8, 122.9, 115.8,

114.8, 107.0, 44.7, 37.4, 23.5, 23.3. **HRMS** (EI-TOF) m/z:  $[M]^+$  calcd for  $C_{14}H_{15}{}^{35}ClN_2O_3$ : 294.0766, found: 294.0770;  $C_{14}H_{15}{}^{37}ClN_2O_3$ : 296.0737, found: 294.0738;  $[\alpha]_D{}^{25} = +13.9$  (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); **HPLC** (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 5.864 min (minor), 15.092 min (major).



(*S*)-5-Methoxy-3-nitro-*N*-phenyl-4-vinyl-4*H*-chromen-2-amine (54): Following the general procedure **A**, compound 54 was obtained as a yellow solid in 80% yield (25.8 mg), 72% ee;  $R_f = 0.5 (CH_2Cl_2)$ ; m.p: 157 – 159 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  12.25 (brs, 1H), 7.43 (d, *J* = 5.8 Hz, 4H), 7.34 – 7.19 (m, 2H), 6.72 (dd, *J* = 13.3, 8.3 Hz, 2H), 6.02 (ddd, *J* = 17.1, 10.0, 5.6 Hz, 1H), 5.23 (d, *J* = 5.7 Hz, 1H), 5.05 (d, *J* = 10.0 Hz, 1H), 4.97 (d, *J* = 17.1 Hz, 1H), 3.88 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  157.2, 157.1, 149.1, 135.8, 135.3, 129.5(2C), 128.7, 126.5, 123.2(2C), 114.7, 112.9, 108.8, 108.5, 107.7, 56.1, 34.3. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub>: 324.1105, found: 324.1111; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +26.9 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); **HPLC** (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 10.010 min (minor), 10.624 min (major).



(*S*)-5-Methoxy-*N*-methyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (55): Following the general procedure **A**, compound **55** was obtained as a yellow solid in 61% yield (15.9mg), 70% ee; R<sub>f</sub> = 0.3 (petroleum ether/ethyl acetate = 4/1); m.p: 149 – 151 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.46 (brs, 1H), 7.28 – 7.19 (m, 1H), 6.76 – 6.71 (m, 2H), 5.99 (ddd, *J* = 17.2, 10.0, 5.5 Hz, 1H), 5.17 (d, *J* = 5.5 Hz, 1H), 5.00 (d, *J* = 10.1 Hz, 1H), 4.89 (d, *J* = 17.1 Hz, 1H), 3.86 (s, 3H), 3.21 (d, *J* = 5.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.3, 157.1, 149.2, 136.0, 128.6, 114.3, 113.1, 108.4, 107.8, 107.5, 56.1, 34.3, 28.0. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>: 262.0948, found: 262.0956; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +41.4 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak IC-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 27.667 min (major), 42.084 min (minor).



(S)-N-Isopropyl-5-methoxy-3-nitro-4-vinyl-4H-chromen-2-amine (56): Following the general procedure A, compound 56 was obtained as a yellow solid in 77% yield (22.3mg), 90%

ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 102 – 104 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.43 (brs, 1H), 7.25 – 7.21 (m, 1H), 6.73 (d, J = 8.2 Hz, 2H), 5.98 (ddd, J = 17.4, 10.1, 5.6 Hz, 1H), 5.17 (d, J = 5.5 Hz, 1H), 5.00 (d, J = 10.1 Hz, 1H), 4.89 (d, J = 17.2 Hz, 1H), 4.35 – 4.20 (m, 1H), 3.86 (s, 3H), 1.40 (d, J = 6.5 Hz, 3H), 1.37 (d, J = 6.5 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.0, 157.1, 149.3, 135.9, 128. 6, 114.2, 113.2, 108.3, 107.4, 107.4, 56.1, 44.5, 34.3, 23.4, 23.2. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub>: 290.1261, found: 290.1265; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +19.2 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 6.278 min (minor), 8.570 min (major).



(*S*)-8-Bromo-3-nitro-*N*-phenyl-4-vinyl-4*H*-chromen-2-amine (57): Following the general procedure **A**, compound **57** was obtained as a yellow solid in 96% yield (35.6mg), 97% ee;  $R_f = 0.6 (CH_2Cl_2)$ ; m.p: 150 – 152 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  12.31 (brs, 1H), 7.58 (d, *J* = 7.9 Hz, 2H), 7.54 – 7.40 (m, 3H), 7.34 – 7.19 (m, 2H), 7.10 – 7.07 (m, 1H), 5.89 (ddd, *J* = 16.7, 10.0, 6.6 Hz, 1H), 5.13 (d, *J* = 10.8 Hz, 1H), 5.08 (d, *J* = 17.6 Hz, 1H), 5.03 (d, *J* = 6.6 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  156.5, 145.5, 136.9, 134.7, 132.6, 129.4(2C), 128.8, 126.9, 126.8, 125.3, 123.9(2C), 116.2, 110.1, 107.9, 39.9. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>79</sup>BrN<sub>2</sub>O<sub>3</sub>: 372.0105, found: 372.0108; C<sub>17</sub>H<sub>13</sub><sup>81</sup>BrN<sub>2</sub>O<sub>3</sub>: 374.0084, found: 372.0093; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +18.0 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 8.177 min (minor), 15.913 min (major).



(*S*)-8-Bromo-*N*-methyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (58): Following the general procedure **A**, compound **58** was obtained as a yellow solid in 97% yield (29.9mg), 61% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 135 – 137 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.28 (brs, 1H), 7.50 (d, *J* = 7.9 Hz, 1H), 7.21 (d, *J* = 7.6 Hz, 1H), 7.08 (dd, *J* = 8.0 Hz, 8.0 Hz, 1H), 5.86 (ddd, *J* = 16.8, 10.0, 6.4 Hz, 1H), 5.07 (d, *J* = 10.2 Hz, 1H), 5.01 (d, *J* = 17.7 Hz, 1H), 4.96 (d, *J* = 7.0 Hz, 1H), 3.31 (d, *J* = 5.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.5, 145.1, 136.9, 132.1, 128.7, 126.5, 125.4, 115.7, 110.3, 106.9, 39.9, 28.5. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>12</sub>H<sub>11</sub><sup>79</sup>BrN<sub>2</sub>O<sub>3</sub>: 309.9948, found: 309.9950; C<sub>12</sub>H<sub>11</sub><sup>81</sup>BrN<sub>2</sub>O<sub>3</sub>: 311.9928, found: 311.9937; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +14.6 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); **HPLC** (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 11.440 min (minor), 43.566 min (major).



(*S*)-8-Bromo-*N*-isopropyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (59): Following the general procedure **A**, compound **59** was obtained as a yellow solid in 86% yield (29.1mg), 59% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 149 – 151 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.24 (brs, 1H), 7.50 (d, *J* = 6.4 Hz, 1H), 7.21 (d, *J* = 5.7 Hz, 1H), 7.10 – 7.06 (m, 1H), 5.86 (ddd, *J* = 16.7, 10.0, 6.4 Hz, 1H), 5.07 (d, *J* = 10.0 Hz, 1H), 5.01 (d, *J* = 16.9 Hz, 1H), 4.97 (d, *J* = 6.4 Hz, 1H), 4.48 – 4.40 (m, 1H), 1.44 (d, *J* = 6.6 Hz, 3H), 1.42 (d, *J* = 6.5 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.2, 145.3, 136.9, 132.1, 128.8, 126.5, 125.5, 115.7, 110.3, 106.5, 45.1, 39.9, 23.3, 23.1. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>14</sub>H<sub>15</sub><sup>79</sup>BrN<sub>2</sub>O<sub>3</sub>: 338.0261, found: 338.0265; C<sub>14</sub>H<sub>15</sub><sup>81</sup>BrN<sub>2</sub>O<sub>3</sub>: 340.0241, found: 340.0247; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +8.3 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 5.785 min (minor), 15.419 min (major).



(*S*)-8-Methyl-3-nitro-*N*-phenyl-4-vinyl-4*H*-chromen-2-amine (60): Following the general procedure **A**, compound **60** was obtained as a yellow solid in 90% yield (27.6mg), 99% ee;  $R_f = 0.6 (CH_2Cl_2)$ ; m.p: 109 – 111 °C; <sup>1</sup>H NMR (400 MHz, CDCl\_3)  $\delta$  12.25 (brs, 1H), 7.48 – 7.42 (m, 4H), 7.33 – 7.30 (m, 1H), 7.12 – 7.07 (m, 3H), 5.92 (ddd, *J* = 16.7, 9.5, 6.6 Hz, 1H), 5.09 (d, *J* = 7.2 Hz, 1H), 5.04 (d, *J* = 16.0 Hz, 1H), 5.00 (d, *J* = 4.2 Hz, 1H), 2.17 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl\_3)  $\delta$  157.2, 146.9, 137.4, 135.0, 130.1, 129.4(2C), 127.2, 126.9, 125.8, 125.7, 124.1(2C), 123.1, 115.6, 108.2, 39.7, 16.3. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>: 308.1155, found: 308.1160; [ $\alpha$ ]p<sup>25</sup> = +15.2 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 8.088 min (minor), 23.630 min (major).



(*S*)-*N*,8-Dimethyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (61): Following the general procedure **A**, compound **61** was obtained as a yellow solid in 90% yield (22.1mg), 62% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 136 – 138 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.43 (brs, 1H), 7.16 – 7.05 (m, 3H), 5.86 (ddd, *J* = 16.7, 10.0, 6.4 Hz, 1H), 5.03 (d, *J* = 10.0 Hz, 1H), 4.98 (d, *J* = 16.8 Hz, 1H), 4.92 (d, *J* = 6.4 Hz, 1H), 3.24 (d, *J* = 5.2 Hz, 3H), 2.37 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.9, 146.7, 137.4, 129.9, 127.2, 125.6, 125.4, 123.1,

115.1, 107.3, 39.7, 28.0, 15.9. **HRMS** (EI-TOF) m/z:  $[M]^+$  calcd for  $C_{13}H_{14}N_2O_3$ : 246.0999, found: 246.1002;  $[\alpha]_D^{25} = +28.7$  (*c* 0.20,  $CH_2Cl_2$ ); **HPLC** (Chiralpak IC-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm)  $t_R = 27.711$  min (major), 36.674 min (minor).



(*S*)-*N*-Isopropyl-8-methyl-3-nitro-4-vinyl-4*H*-chromen-2-amine (62): Following the general procedure **A**, compound **62** was obtained as a yellow solid in 90% yield (24.7mg), 55% ee;  $R_f = 0.4$  (petroleum ether/ethyl acetate = 4/1); m.p: 132 – 134 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.43 (brs, 1H), 7.15 – 7.06 (m, 3H), 5.87 (ddd, *J* = 16.6, 10.0, 6.4 Hz, 1H), 5.04 (d, *J* = 9.9 Hz, 1H), 4.99 (d, *J* = 16.9 Hz, 1H), 4.93 (d, *J* = 6.3 Hz, 1H), 4.36 – 4.23 (m, 1H), 2.37 (s, 3H), 1.43 (d, *J* = 6.5 Hz, 3H), 1.40 (d, *J* = 6.5 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.5, 146.7, 137.4, 129.9, 127.2, 125.5, 125.3, 123.2, 115.1, 106.8, 44.6, 39.7, 23.2, 23.1, 15.9. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>: 274.1312, found: 274.1320; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +5.8 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 5.749 min (minor), 68.704 min (major).



**General procedure B**: Under a nitrogen atmosphere, a flame dried 10 mL Schlenk tube was charged with  $[Ir(cod)Cl]_2$  (2.7 mg, 0.004 mmol, 4 mol%), Carreira's ligand (*S*)-L1 (8.2 mg, 0.016 mmol, 16 mol%). After the tube was evacuated and backfilled with nitrogen, freshly distilled THF (1.5 mL) was added, then stirred at room temperature for 15 minutes while the solution turned dark red. Then, 2-(1-hydroxyallyl)phenols (±)-1 (0.2 mmol, 2.0 equiv) were added and the reaction mixture immediately turned light yellow. Malononitrile (6.6 mg, 0.1 mmol, 1.0 equiv) and Nd(OTf)<sub>3</sub> (13.9 mg, 0.02 mmol, 20 mol%) were added sequentially. The reaction mixture was stirred at room temperature until 1 were consumed (monitored by TLC), which was directly purified by flash column chromatography silica gel (petroleum ether/ethyl acetate = 4/1) to afford products **63-69**.



(S)-2-Amino-4-vinyl-4*H*-chromene-3-carbonitrile (63): Following the general procedure **B**, compound 63 was obtained as a yellow solid in 73% yield (14.5 mg), 88% ee;  $R_f = 0.3$  (petroleum ether/ethyl acetate = 4/1); m.p: 104 – 106 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.23

-7.09 (m, 3H), 6.95 (d, J = 8.1 Hz, 1H), 5.78 (ddd, J = 17.6, 9.1, 8.3 Hz, 1H), 5.22 (d, J = 16.9 Hz, 1H), 5.13 (d, J = 9.8 Hz, 1H), 4.69 (brs, 2H), 4.13 (d, J = 8.3 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 159.7, 148.5, 139.7, 129.4, 128.5, 125.0, 121.4, 120.1, 116.5, 115.9, 58.2, 39.5. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>12</sub>H<sub>10</sub>N<sub>2</sub>O: 198.0788, found: 198.0791; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = -0.6 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 6.609 min (minor), 7.547 min (major).

(*R*)-2-Amino-5-chloro-4-vinyl-4*H*-chromene-3-carbonitrile (64): Following the general procedure **B**, compound 64 was obtained as a white solid in 40% yield (9.3 mg), 89% ee;  $R_f = 0.3$  (petroleum ether/ethyl acetate = 4/1); m.p: 123 – 125 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.23 – 7.13 (m, 2H), 6.92 (dd, J = 6.7, 2.7 Hz, 1H), 5.83 (ddd, J = 16.8, 9.9, 6.7 Hz, 1H), 5.16 (d, J = 16.8 Hz, 1H), 5.13 (d, J = 10.4 Hz, 1H), 4.69 (brs, 2H), 4.32 (d, J = 6.4 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.1, 150.1, 136.9, 133.9, 128.7, 126.2, 121.3, 119.5, 115.9, 115.3, 58.7, 37.5. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>12</sub>H<sub>9</sub><sup>35</sup>ClN<sub>2</sub>O: 232.0398, found: 232.0404; C<sub>12</sub>H<sub>9</sub><sup>37</sup>ClN<sub>2</sub>O: 234.0369, found: 234.0372; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = -3.2 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 5.788 min (major), 8.816 min (minor).



(*S*)-2-Amino-6-fluoro-4-vinyl-4*H*-chromene-3-carbonitrile (65): Following the general procedure **B**, compound 65 was obtained as a yellow solid in 66% yield (15.3 mg), 71% ee; R<sub>f</sub> = 0.3 (petroleum ether/ethyl acetate = 4/1); m.p: 141 – 143 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.98 – 6.87 (m, 2H), 6.86 (d, J = 7.8 Hz, 1H), 5.76 (ddd, J = 16.8, 9.6, 8.3 Hz, 1H), 5.25 (d, J = 16.8 Hz, 1H), 5.18 (d, J = 9.7 Hz, 1H), 4.61 (brs, 2H), 4.12 (d, J = 8.4 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 159.5, 159.4 (d, <sup>1</sup>*J* <sub>C-F</sub> = 242.3 Hz), 144.6, 138.9, 123.2 (d, <sup>3</sup>*J* <sub>C-F</sub> = 7.8 Hz), 119.7, 117.9 (d, <sup>3</sup>*J* <sub>C-F</sub> = 8.6 Hz), 116.8, 115.5 (d, <sup>2</sup>*J* <sub>C-F</sub> = 23.6 Hz), 115.4 (d, <sup>2</sup>*J* <sub>C-F</sub> = 23.8 Hz), 57.9, 39.8. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ -117.32 – -117.41 (m). HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>12</sub>H<sub>9</sub>FN<sub>2</sub>O: 216.0693, found: 216.0697; [α]<sub>D</sub><sup>25</sup> = -1.8 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 6.630 min (minor), 7.438 min (major).



(S)-2-Amino-6-methoxy-4-vinyl-4*H*-chromene-3-carbonitrile (66): Following the general procedure **B**, compound 66 was obtained as a yellow solid in 70% yield (15.9 mg), 90% ee;  $R_f$ 

= 0.3 (petroleum ether/ethyl acetate = 4/1); m.p: 167 – 169 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.89 (d, J = 8.9 Hz, 1H), 6.76 (dd, J = 8.9, 3.0 Hz, 1H), 6.64 (d, J = 2.9 Hz, 1H), 5.77 (ddd, J = 16.8, 9.8, 8.4 Hz, 1H), 5.24 (d, J = 16.8 Hz, 1H), 5.15 (d, J = 10.0 Hz, 1H), 4.57 (brs, 2H), 4.11 (d, J = 8.4 Hz, 1H), 3.77 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.8, 156.6, 142.6, 139.5, 122.2, 120.2, 117.4, 116.1, 114.4, 113.4, 57.9, 55.8, 39.9. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>13</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>: 228.0899, found: 228.0896; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = -2.7 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AD-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 9.352 min (minor), 14.632 min (major).



(*S*)-2-Amino-7-methyl-4-vinyl-4*H*-chromene-3-carbonitrile (67): Following the general procedure **B**, compound 67 was obtained as a white solid in 54% yield (11.4 mg), 96% ee;  $R_f = 0.3$  (petroleum ether/ethyl acetate = 4/1); m.p: 140 – 142 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.03 (d, J = 7.8 Hz, 1H), 6.93 (dd, J = 7.8, 1.7 Hz, 1H), 6.77 (s, 1H), 5.75 (ddd, J = 16.8, 9.7, 8.3 Hz, 1H), 5.21 (d, J = 16.8 Hz, 1H), 5.12 (d, J = 9.7 Hz, 1H), 4.57 (brs, 2H), 4.10 (d, J = 8.3 Hz, 1H), 2.32 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.6, 148.4, 139.8, 138.8, 129.1, 125.9, 120.1, 118.3, 116.8, 115.8, 58.6, 39.3, 21.1. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>13</sub>H<sub>12</sub>N<sub>2</sub>O: 212.0944, found: 212.0948; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = -3.1 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AD-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda = 220$  nm) t<sub>R</sub> = 7.529 min (minor), 12.306 min (major).



(*S*)-2-Amino-7-chloro-4-vinyl-4*H*-chromene-3-carbonitrile (68): Following the general procedure **B**, compound 68 was obtained as a white solid in 59% yield (13.7 mg), 97% ee; R<sub>f</sub> = 0.3 (petroleum ether/ethyl acetate = 4/1); m.p: 125 – 127 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.09 (d, *J* = 1.5 Hz, 2H), 6.98 (s, 1H), 5.74 (ddd, *J* = 16.8, 9.8, 8.3 Hz, 1H), 5.23 (d, *J* = 16.8 Hz, 1H), 5.16 (d, *J* = 9.8 Hz, 1H), 4.66 (brs, 2H), 4.10 (d, *J* = 8.3 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.2, 148.9, 139.2, 133.7, 130.4, 125.3, 120.1, 119.6, 116.8, 116.5, 58.6, 39.2. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>12</sub>H<sub>9</sub><sup>35</sup>ClN<sub>2</sub>O: 232.0398, found: 232.0404; C<sub>12</sub>H<sub>9</sub><sup>37</sup>ClN<sub>2</sub>O: 234.0369, found: 234.0376; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +0.8 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 6.026 min (minor), 6.994 min (major).



(*S*)-2-Amino-8-bromo-4-vinyl-4*H*-chromene-3-carbonitrile (69): Following the general procedure **B**, compound 69 was obtained as a yellow solid in 54% yield (12.3 mg), 95% ee;  $R_f = 0.3$  (petroleum ether/ethyl acetate = 4/1); m.p: 157 – 159 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.45 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.11 (d, *J* = 7.4 Hz, 1H), 7.01 – 6.97 (m, 1H), 5.77 (ddd, *J* = 16.8, 9.8, 8.2 Hz, 1H), 5.23 (d, *J* = 16.8 Hz, 1H), 5.16 (d, *J* = 9.8 Hz, 1H), 4.74 (brs, 2H), 4.16 (d, *J* = 8.3 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.3, 145.6, 139.2, 132.4, 128.6, 125.7, 123.5, 119.4, 116.5, 110.5, 58.8, 40.0. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>12</sub>H<sub>9</sub><sup>79</sup>BrN<sub>2</sub>O: 275.9893, found: 275.9901; C<sub>12</sub>H<sub>9</sub><sup>81</sup>BrN<sub>2</sub>O: 277.9873, found: 277.9881; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = -2.4 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AD-H, *n*-hexane/ethanol = 80/20, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 7.398 min (minor), 10.674 min (major).

The preparation and X-ray analysis of the single crystal: Compound 69 (95% ee, 10.0 mg) was dissolved in 1.0 mL of acetone in a screw-top vial and drops of hexane were added. The lid was then loosely screwed on the vial, and a single crystal was obtained by natural volatilization at room temperature. The data set was collected by a Bruker APEX-II CCD at 293(2) K equipped with Cu radiation source (K $\alpha$  = 1.54178 Å). Applied with multi-scan absorption correction, the structure solution was solved and refinement was processed by SHELXTL program package. CCDC 2342670 contains the supplementary crystallographic data, and can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html.



Figure S2. The thermal ellipsoid plot for X-ray structure of compound 69 with the ellipsoid

contour at 30% probability levels

Crystal data and structure refinement for 69				
Identification code	zm_e123_0m			
Empirical formula	$C_{12}H_9BrN_2O$			
Formula weight	277.12			
Temperature	293.00 K			
Wavelength	1.54178 Å			
Crystal system	Monoclinic			
Space group	P 1 21 1			
Unit cell dimensions	a = 4.9753(2) Å	a= 90 °.		
	633			

	b = 16.0176(6) Å c = 14.3810(5) Å	b= 90.798(2) °. g= 90 °.	
Volume	1145.94(7) Å <sup>3</sup>		
Z	4		
Density (calculated)	1.606 Mg/m <sup>3</sup>		
Absorption coefficient	4.724 mm <sup>-1</sup>		
F(000)	552		
Crystal size	0.2 x 0.15 x 0.13 mm <sup>3</sup>		
Theta range for data collection	3.073 to 68.389°.		
Index ranges	-5<=h<=5, -19<=k<=19, -17<=l<=15		
Reflections collected	14310		
Independent reflections	4023 [R(int) = 0.0910]		
Completeness to theta = $67.679^{\circ}$	99.5 %		
Absorption correction	Semi-empirical from equiva	alents	
Max. and min. transmission	x. and min. transmission 0.7531 and 0.5321		
Refinement method	Full-matrix least-squares on	$1 F^2$	
Data / restraints / parameters	4023 / 2 / 303		
Goodness-of-fit on $F^2$	0.940		
Final R indices [I>2sigma(I)]	R1 = 0.0474, wR2 = 0.1241		
R indices (all data)	R1 = 0.0773, $wR2 = 0.1295$		
Absolute structure parameter	0.12(2)		
Extinction coefficient	n/a		
Largest diff. peak and hole	0.483 and -0.685 e.Å <sup>-3</sup>		

#### 4. Gram-scale preparation of products 47 and 63



Under a nitrogen atmosphere, a flame dried 100 mL Schlenk tube was charged with  $[Ir(cod)Cl]_2$  (67 mg, 0.1 mmol, 1 mol %), Carreira's ligand (*S*)-L1 (203 mg, 0.4 mmol, 4 mol %). After the tube was evacuated and backfilled with nitrogen, freshly distilled CH<sub>2</sub>Cl<sub>2</sub> (40 mL) was added, then stirred at room temperature for 15 minutes while the solution turned dark red. Then, 2-(1-hydroxyallyl)phenol 1b (3.68 g, 20 mmol, 2.0 equiv) were added and the reaction mixture immediately turned light yellow. 1-(methylthio)-2-nitroenamine 2b (1.48 g, 10 mmol, 1.0 equiv) and Ce(OTf)<sub>3</sub> (1.17 g, 2 mmol, 20 mol %) were added sequentially. The reaction mixture was stirred at room temperature until 2b were consumed (monitored by TLC). After the solvent was removed in vacuo, the residue was directly purified by flash column chromatography silica gel (petroleum ether/ethyl acetate = 4/1) to afford product 47 in 75% yield (1.99 g, 89% ee).



Under a nitrogen atmosphere, a flame dried 100 mL Schlenk tube was charged with  $[Ir(cod)Cl]_2$  (67 mg, 0.1 mmol, 1 mol %), Carreira's ligand (*S*)-L1 (203 mg, 0.4 mmol, 4 mol %). After the tube was evacuated and backfilled with nitrogen, freshly distilled THF (40 mL) was added, then stirred at room temperature for 15 minutes while the solution turned dark red. Then, racemic allylic alcohol 1a (3.00 g, 20 mmol, 2.0 equiv) were added and the reaction mixture immediately turned light yellow. Malononitrile (0.66 g, 10 mmol, 1.0 equiv) and Nd(OTf)<sub>3</sub> (1.39 g, 2 mmol, 20 mol %) were added sequentially. The reaction mixture was stirred at room temperature until 1a were consumed (monitored by TLC). After the solvent was removed in vacuo, the residue was directly purified by flash column chromatography silica gel (petroleum ether/ethyl acetate = 4/1) to afford product 63 in 64% yield (1.27 g, 85% ee).

#### 5. Synthetic transformation of product 47



Under a nitrogen atmosphere, a flame dried 10 mL Schlenk tube was charged with compound 47 (53.2 mg, 0.2 mmol, 1.0 equiv), 4-iodobenzyl ether (93.6 mg, 0.4 mmol, 2.0 equiv), DIPEA (258.5 mg, 2 mmol, 10.0 equiv) and PdCl<sub>2</sub> (7.1 mg, 0.04 mmol, 20 mmol%), after the tube was evacuated and backfilled with nitrogen, dry THF (3 mL) was added, then the reaction mixture was stirred at 60 °C for 12 hours. Afterwards, the solvent was removed *in vacuo*, and the crude product was extracted with EtOAc (5 mL) 3-5 times. The combined organics was washed with water and brine, then separated, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated under the reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 4/1) to give the desired product **70**.

(*S,E*)-7-Chloro-4-(4-methoxystyryl)-*N*-methyl-3-nitro-4*H*-chromen-2-amine (70): yellow solid, 34% yield (25.3 mg), 87% ee;  $R_f = 0.2$  (petroleum ether/ethyl acetate = 4/1); m.p: 136 – 138 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.40 (brs, 1H), 7.26 – 7.16 (m, 5H), 6.79 (d, *J* = 8.5 Hz, 2H), 6.29 (d, *J* = 15.7 Hz, 1H), 6.03 (dd, *J* = 15.7, 7.0 Hz, 1H), 5.04 (d, *J* = 7.0 Hz, 1H), 3.77 (s, 3H), 3.22 (d, *J* = 5.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 159.5, 159.4, 148.5, 133.8, 130.9, 130.5, 129.4, 127.8 (2C), 126.5 (2C), 126.3, 122.5, 116.8, 114.0 (2C), 55.4, 38.6, 28.1. HRMS (EI-TOF) m/z: [M]<sup>+</sup> calcd for C<sub>19</sub>H<sub>17</sub><sup>35</sup>ClN<sub>2</sub>O<sub>4</sub>: 372.0871, found: 372.0881; C<sub>19</sub>H<sub>17</sub><sup>37</sup>ClN<sub>2</sub>O<sub>4</sub>: 374.0847, found: 374.0854;  $[\alpha]_D^{25} = +13.1$  (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AS-H, *n*-hexane/ethanol = 70/30, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 17.555 min (minor), 40.391 min (major).



A flame-dried Schlenk tube was charged compound **47** (53.2 mg, 0.2 mmol, 1.0 equiv) and purged with nitrogen.  $CH_2Cl_2$  (1.0 mL) was added *via* syringe to the reaction tube. A second flame-dried tube was charged with  $\alpha$ -chlorobenzaldoxime (155.6 mg, 1.00 mmol, 5.0 equiv.) and  $CH_2Cl_2$  (2.0 mL) and purged with nitrogen. Triethylamine (139.0  $\mu$ L, 1.00 mmol, 5.0 equiv.) was added to the second tube, which was stirred 15 minutes at room temperature. The oxime chloride solution was then transferred to the tube containing **47** *via* syringe. The mixture was stirred 12 hours at room temperature. After completion, the reaction mixture was quenched with
water and extracted with  $CH_2Cl_2$  for three times. The resulted filtrate was separated. The combined organic phase was washed with brine, dried over  $Na_2SO_4$  and concentrated under reduced pressure. The crude mixture was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 4:1) to give product **71** as a white solid in 90% yield (69.3 mg, 88% ee, 6:1 dr).

(*S*)-7-Chloro-*N*-methyl-3-nitro-4-((*S*)-3-phenyl-4,5-dihydroisoxazol-5-yl)-4*H*-chromen-2amine (71): white solid, 90% yield (69.3 mg), 88% ee;  $R_f = 0.2$  (petroleum ether/ethyl acetate = 4:1); m.p: 124 – 126 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.37 (brs, 1H), 7.50 – 7.42 (m, 3H), 7.38 – 7.32 (m, 3H), 7.21 – 7.16 (m, 1H), 7.13 (d, *J* = 2.1 Hz, 1H), 5.17 (ddd, *J* = 11.0, 8.1, 3.0 Hz, 1H), 4.90 (d, *J* = 3.0 Hz, 1H), 3.31 – 3.25 (dd, *J* = 11.0, 8.1 Hz, 1H), 3.23 (d, *J* = 5.2 Hz, 3H), 2.94 (dd, *J* = 17.0, 8.1 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.7, 156.9, 149.6, 134.4, 131.3, 130.3, 129.1, 128.8 (2C), 126.7 (2C), 126.4, 119.4, 116.4, 104.3, 82.5, 39.1, 36.9, 28.3. HRMS (ESI-TOF) m/z: [M+Na]<sup>+</sup> calcd for C<sub>19</sub>H<sub>16</sub><sup>35</sup>ClN<sub>3</sub>O<sub>4</sub>Na: 408.0722, found: 408.0726; C<sub>19</sub>H<sub>16</sub><sup>37</sup>ClN<sub>3</sub>O<sub>4</sub>Na: 410.0693, found: 410.0698; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +11.3 (*c* 0.20, CH<sub>2</sub>Cl<sub>2</sub>); HPLC (Chiralpak AD-H, *n*-hexane/ethanol = 70/30, flow rate = 1.0 mL/min,  $\lambda$  = 220 nm) t<sub>R</sub> = 18.260 min (minor-1), 21.850 min (major-1), 23.696 min (minor-2), 25.159 min (major-2).

#### 6. Antifungal activities evaluation

In-vitro antifungal activities of 2-amino-4H-chromene compounds against Fusarium graminearum, Botrytis cinerea, Rhizoctonia solani and Sclerotinia sclerotiorum, which were provided by GreenTech Laboratory, were tested using the mycelium growth rate method. All compounds were tested at 100 mg/L as well as the positive control reagents boscalid and procymidone. Each compound was dissolved with dimethyl sulfoxide (DMSO) for preparing 1000 mg/L stock solution and diluted with the melted potato dextrose agar (PDA) media to prepared the target concentrations of compounds. A blank control was established by incorporating 0.5% DMSO (v/v) into PDA media. The mycelial disks, with a diameter of 5 mm, from phytopathogenic fungi were placed onto PDA plates and then were incubated at 25 °C under 80% moisturizing conditions in the dark. Diameters (mm) of the colony were measured by the cross-bracketing method. The growth inhibition rates were calculated according to the following formula percentage inhibition (%) =  $[(C - T)/(C - 5 \text{ mm})] \times 100$ , where C and T represent diameters of the colony cultured on blank control and dosed PDA, respectively. The potent products, which average inhibitory rate >80% at 100 mg/L against Rhizoctonia solani, was further evaluated by the median effective concentrations (EC<sub>50</sub>). Each experiment was conducted three times, and the statistical analyses of the data were performed using Office Excel 19.0. EC<sub>50</sub> values were calculated with the IBM SPSS Statistics 27.0 software.

entry	compounds —	Inhibition Rate (%) (100 mg/L)				
		$F. g.^a$	$B. c.^{b}$	$R. s.^{c}$	$S. s.^d$	
1	rac-3	41.6	40.9	59.7	12.5	
2	rac-4	9.1	10.1	11.2	12.0	
3	rac-5	19.2	24.1	55.7	26.3	
4	rac-6	11.9	-2.5	53.8	10.8	
5	rac-7	23.6	9.2	52.4	-16.1	
6	rac-8	28.3	10.3	57.9	9.6	
7	rac-9	43.6	23.7	47.9	33.5	
8	rac-10	28.8	5.4	38.4	18.1	
9	rac-11	9.6	2.5	46.5	-5.1	
10	rac-12	27.1	5.7	54.9	-4.6	
11	rac-13	54.4	33.1	62.5	10.2	
12	rac-14	32.0	24.4	43.0	25.4	
13	rac-15	65.0	40.5	68.1	11.8	
14	rac-16	52.2	59.0	79.5	42.4	
15	rac-17	58.6	35.1	86.9	66.5	
16	rac-18	49.4	47.0	86.8	48.3	
17	rac-19	54.7	38.0	90.7	27.2	
18	rac-20	-6.1	-3.1	24.9	2.8	
19	rac-21	43.7	66.7	66.7	59.8	
20	rac-22	57.7	68.4	85.9	64.1	
21	rac-23	29.4	43.3	86.8	28.5	
22	rac-24	15.5	18.0	83.1	5.6	

Fable S3	In vitro	antifungal	activities	of 3-70
----------	----------	------------	------------	---------

23	rac-25	18.5	9.6	46.7	3.9
24	rac-26	62.6	37.6	61.8	29.2
25	rac-27	32	36.1	43.2	8.2
26	rac-28	21.9	22.5	56.4	44.9
27	rac-29	74.1	57.3	61.2	47.8
28	rac-30	23.7	18.6	41.6	10.8
29	rac-31	42.3	30.7	65.4	25.7
30	rac-32	64.9	39.1	64.8	33.9
31	rac-33	22.4	18.3	35.9	19.2
32	rac-34	-15.6	-19.5	2.4	-28.4
33	rac-35	61.3	66.4	67.9	48.8
34	rac-36	76.0	71.5	89.9	30.6
35	rac-37	-4.4	-15.7	25.5	17.9
36	rac-38	64.5	50.7	60.1	41.6
37	rac-39	57.5	61.7	72.7	51
38	rac-40	29.6	-14.6	47.3	-16.0
39	rac-41	67.4	50.7	78.4	27.8
40	rac-42	49.2	52.6	78.2	32.9
41	rac-43	35.7	12.0	40.0	22.5
42	rac-44	67.1	68.3	87.3	62.0
43	rac-45	1.6	10.2	20.0	4.9
44	rac-46	-11.3	-3.8	-4.9	5.5
45	rac-47	81.2	87.6	90.0	74.0
46	rac-48	30.7	8.0	22.1	4.7
47	rac-49	15.0	21.7	46.0	13.9
48	rac-50	45.3	34.7	75.8	32.5
49	rac-51	-14.7	-6.1	29.7	-10.7
50	rac-52	47.6	76.6	70.9	55.4
51	rac-53	49.2	32.5	58.5	16.1
52	rac-54	-10.4	-17.2	10.3	-18.2
53	rac-55	64.9	56.2	70.1	50.8
54	rac-56	41.5	39.1	62.9	29.6
55	rac-57	-8.7	8.8	16.4	1.9
56	rac-58	75.1	67.5	78.4	51.4
57	rac-59	6.1	12.1	40.4	5.5
58	rac-60	36.4	18.0	50.3	26.2
59	rac-61	71.9	69.0	86.4	49.6
60	rac-62	42.8	16.8	37.1	5.5
61	rac-63	18.7	44.7	52.9	33.5
62	rac-64	35.7	48.9	50.8	37.6
63	rac-65	34.3	46.7	56.1	26.4
64	rac-66	26.9	39.6	43.2	29.7
65	rac-67	44.6	56.2	49.8	12.5
66	rac-68	38.6	43.1	60.3	19.8

67	rac-69	39.5	33.7	63.2	20.4
68	rac-70	33.6	35.6	49.4	18.7
69 <sup>e</sup>	Boscalid	35.7	89.6	94.9	94.4
70 <sup>f</sup>	Procymidone	22.2	99.0	98.3	99.7

<sup>a</sup> Fusarium graminearum.

<sup>b</sup> Botrytis cinerea.

<sup>c</sup> Rhizoctonia solani.

<sup>d</sup> Sclerotinia sclerotiorum.

<sup>ef</sup> positive control.

	8	-			
	Rhizoctonia solani				
entry	compounds	y=ax+b	EC <sub>50</sub>	R <sup>2</sup>	95%Cl
			(mg/L)		(mg/L)
1	rac-15	y=1.53x-2.58	47.03	0.97	38.99-58.81
2	rac-16	y=2.32x-3.95	49.15	0.97	43.15-56.78
3	rac-17	y=1.43x-1.96	23.88	0.98	19.64-28.97
4	rac-18	y=1.63x-2.46	31.77	0.89	16.98-71.86
5	rac-19	y=1.62x-2.25	24.21	0.98	20.30-28.80
6	rac-22	y=1.39x-2.13	35.37	0.91	20.03-83.38
7	rac-23	y=1.90x-2.94	32.93	0.84	19.69-50.28
8	rac-24	y=1.56x-2.15	24.08	0.99	20.14-28.75
9	rac-36	y=1.60x-2.21	24.17	0.99	20.30-28.72
10	rac-44	y=2.13x-2.79	22.35	0.95	21.59-29.65
11	rac-47	y=1.94x-2.65	22.01	0.99	18.65-25.89
12	<i>(S)</i> -47	y=1.20x-1.54	19.41	0.96	15.14-24.31
13	( <i>R</i> )-47	y=1.24x-1.53	17.43	0.93	8.59-28.73
14	rac-61	y=1.83x-2.55	25.29	0.98	21.59-29.65

## Table S4 EC<sub>50</sub> Values against *Rhizoctonia solani*

#### 7. References

[1] C. Defieber, M. A. Ariger, P. Moriel, E. M. Carreira, Iridium-Catalyzed Synthesis of Primary Allylic Amines from Allylic Alcohols: Sulfamic Acid as Ammonia Equivalent, *Angew. Chem. Int. Ed.* 2007, **46**, 3139-3143.

[2] J. Zhang, W. L. Yang, H. Zheng, Y. Wang, W.-P. Deng, Regio- and Enantioselective γ-Allylic Alkylation of In Situ-Generated Free Dienolates via Scandium/Iridium Dual Catalysis, *Angew. Chem. Int. Ed.* 2022, **61**, e202117079.

[3] C. Venkatesh, B. Singh, P. K. Mahata, H. Ila, H. Junjappa, Heteroannulation of Nitroketene *N*,*S*-Arylaminoacetals with POCl<sub>3</sub>: A Novel Highly Regioselective Synthesis of Unsymmetrical 2,3-Substituted Quinoxalines, *Org. Lett.* 2005, **7**, 2169-2172.

## 8. <sup>1</sup>H NMR, <sup>13</sup>C NMR and <sup>19</sup>F NMR spectra

<sup>1</sup>H NMR (400 MHz) of **3** in CDCl<sub>3</sub>



f1 (ppm)

<sup>1</sup>H NMR (400 MHz) of 4 in CDCl<sub>3</sub>



 $^{19}\mathrm{F}$  NMR (376 MHz) of 4 in CDCl<sub>3</sub>







 $^{19}F$  NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -110.48 – -110.55(m).

<sup>1</sup>H NMR (400 MHz) of **5** in CDCl<sub>3</sub>



<sup>1</sup>H NMR (400 MHz) of 6 in CDCl<sub>3</sub>



 $^{19}\mathrm{F}$  NMR (376 MHz) of **6** in CDCl<sub>3</sub>







<sup>1</sup>H NMR (400 MHz) of 7 in CDCl<sub>3</sub>





<sup>1</sup>H NMR (400 MHz) of 8 in CDCl<sub>3</sub>



<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 156.7, 148.1, 137.1, 134.4, 132.7(2C), 129.8, 128.7, 126.3, 124.9(2C), 123.2, 119.9, 116.3, 115.9, 108.6, 39.6.













<sup>1</sup>H NMR (400 MHz) of **12** in CDCl<sub>3</sub>



<sup>1</sup>H NMR (400 MHz) of **13** in CDCl<sub>3</sub>







S56







<sup>1</sup>H NMR (400 MHz) of 18 in CDCl<sub>3</sub>











## <sup>19</sup>F NMR (376 MHz) of **20** in CDCl<sub>3</sub>





-10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 f1 (ppm)





<sup>1</sup>H NMR (400 MHz) of **22** in CDCl<sub>3</sub>



<sup>1</sup>H NMR (400 MHz) of 23 in CDCl<sub>3</sub>



<sup>1</sup>H NMR (400 MHz) of **24** in CDCl<sub>3</sub>



<sup>1</sup>H NMR (400 MHz) of **25** in CDCl<sub>3</sub>



## $^{19}\text{F}$ NMR (376 MHz) of **25** in CDCl<sub>3</sub>





-10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 f1 (ppm)





 $^{19}\text{F}$  NMR (376 MHz) of  $\mathbf{26}$  in CDCl<sub>3</sub>

-116.187 -116.199 -116.208 -116.220 -116.229 -116.229



-10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 f1 (ppm) <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ -116.21 - -116.24(m). <sup>1</sup>H NMR (400 MHz) of **27** in CDCl<sub>3</sub>



# $^{19}\text{F}$ NMR (376 MHz) of 27 in CDCl3



-10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)

-116.305 -116.319 -116.328 -116.335 -116.335








<sup>1</sup>H NMR (400 MHz) of **30** in CDCl<sub>3</sub>



<sup>1</sup>H NMR (400 MHz) of **31** in CDCl<sub>3</sub>

















<sup>1</sup>H NMR (400 MHz) of **36** in CDCl<sub>3</sub> - 10.476 7,075 7,075 6,9955 6,9956 6,9956 5,5046 5,5036- 0.000 / NO<sub>2</sub> Me Me N H Мe 0.93<del>.</del>] 1.00 3.01 3.01 H00.1 1.00 3.00-1.00 11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 -1.0 f1 (ppm) <sup>13</sup>C NMR (100 MHz) of **36** in CDCl<sub>3</sub> -- 158.795 137.411 135.559 129.854 129.043 123.102 115.758 -- 44.399 -- 39.650 - 23.379 - 23.198 - 20.874 77.478 77.160 76.843 NO<sub>2</sub> Me Me С Мe 210 200 190 180 170 160 150 140 130 120 110 100 90 f1 (ppm) -10 80 10 70 60 50 40 30 20 Ò















## $^{19}\mathrm{F}$ NMR (376 MHz) of 40 in CDCl<sub>3</sub>











<sup>1</sup>H NMR (400 MHz) of **42** in CDCl<sub>3</sub>





11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 -1.0 f1 (ppm)

<sup>13</sup>C NMR (100 MHz) of 42 in CDCl<sub>3</sub>



## $^{19}\mathrm{F}$ NMR (376 MHz) of **42** in CDCl<sub>3</sub>









<sup>1</sup>H NMR (400 MHz) of 45 in CDCl<sub>3</sub>







**S94** 



<sup>1</sup>H NMR (400 MHz) of **48** in CDCl<sub>3</sub>





<sup>1</sup>H NMR (400 MHz) of 49 in CDCl<sub>3</sub> - 10.266 - 7.193 5.882 5.866 5.857 5.840 5.840 5.815 5.815 NO<sub>2</sub> CI 0.95 1.00<u>H</u> 2.00-2.00-1 3.00-₌ 1.00 Ho.I 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 -1.0 f1 (ppm) <sup>13</sup>C NMR (100 MHz) of **49** in CDCl<sub>3</sub> / 137.051
/ 133.765
/ 133.766
/ 130.706
/ 126.129
/ 122.045
/ 116.834
/ 115.847 - 160.450 -- 24.001 77.478 77.160 76.842 - 39.221 - 7.478 - 7.456 NO<sub>2</sub> CI С N 210 200 190 180 170 160 150 140 130 120 110 100 90 f1 (ppm) 80 70 50 40 10 ò -10 60 30 20

<sup>1</sup>H NMR (400 MHz) of **50** in CDCl<sub>3</sub>





<sup>1</sup>H NMR (400 MHz) of **51** in CDCl<sub>3</sub>







<sup>1</sup>H NMR (400 MHz) of **53** in CDCl<sub>3</sub>







<sup>1</sup>H NMR (400 MHz) of 55 in CDCl<sub>3</sub>



<sup>1</sup>H NMR (400 MHz) of 56 in CDCl<sub>3</sub>













<sup>1</sup>H NMR (400 MHz) of **59** in CDCl<sub>3</sub>



<sup>1</sup>H NMR (400 MHz) of **60** in CDCl<sub>3</sub>



.....




<sup>1</sup>H NMR (400 MHz) of **62** in CDCl<sub>3</sub>











 $^{19}\mathrm{F}$  NMR (376 MHz) of **65** in CDCl<sub>3</sub>

-117.335 -117.352 -117.369 -117.369 -117.375



-10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)











S117



<sup>1</sup>H NMR (400 MHz) of **70** in CDCl<sub>3</sub>









## **9. HPLC Chromatograms**

HPLC chromatogram of compound 3 (96% ee)



HPLC chromatogram of compound 4 (95% ee)



## HPLC chromatogram of compound 5 (89% ee)



HPLC chromatogram of compound 6 (90% ee)



HPLC chromatogram of compound 7 (94% ee)



HPLC chromatogram of compound 8 (98% ee)

2

total

23.178

742487

766962



41296646

41751677

98.910

100.000

HPLC chromatogram of compound 9 (85% ee)



HPLC chromatogram of compound 10 (93% ee)



HPLC chromatogram of compound 11 (50% ee)



HPLC chromatogram of compound 12 (92% ee)



HPLC chromatogram of compound 13 (96% ee)



HPLC chromatogram of compound 14 (91% ee)



HPLC chromatogram of compound 15 (82% ee)



HPLC chromatogram of compound 16 (65% ee)



HPLC chromatogram of compound 17 (69% ee)



HPLC chromatogram of compound 18 (75% ee)



HPLC chromatogram of compound 19 (72% ee)



HPLC chromatogram of compound 20 (83% ee)



HPLC chromatogram of compound 21 (77% ee)



HPLC chromatogram of compound 22 (60% ee)





HPLC chromatogram of compound 23 (70% ee)



HPLC chromatogram of compound 24 (69% ee)



HPLC chromatogram of compound 25 (87% ee)



HPLC chromatogram of compound 26 (88% ee)


HPLC chromatogram of compound 27 (79% ee)



	1					
	5.0	7.5 10.0	12.5	15.0	17.5	min
#	Ret Time (min)	Height (µV)	Area (µV.sec)	Area (%)		
1	5.905	208647	2183942	10.690		
2	17.752	560621	18245914	89.310		
tota	1	769268	20429856	100.000		

HPLC chromatogram of compound 28 (96% ee)



HPLC chromatogram of compound 29 (86% ee)



HPLC chromatogram of compound 30 (90% ee)



HPLC chromatogram of compound **31** (95% ee)



HPLC chromatogram of compound 32 (78% ee)



HPLC chromatogram of compound 33 (84% ee)



HPLC chromatogram of compound 34 (89% ee)



HPLC chromatogram of compound 35 (64% ee)



HPLC chromatogram of compound 36 (65% ee)



HPLC chromatogram of compound 37 (99% ee)



HPLC chromatogram of compound **38** (52% ee)



HPLC chromatogram of compound 39 (41% ee)



HPLC chromatogram of compound 40 (90% ee)



HPLC chromatogram of compound 41 (77% ee)



HPLC chromatogram of compound 42 (84% ee)



HPLC chromatogram of compound 43 (95% ee)



HPLC chromatogram of compound 44 (74% ee)



HPLC chromatogram of compound 45 (64% ee)



HPLC chromatogram of compound 46 (88% ee)



HPLC chromatogram of compound 47 (89% ee)



HPLC chromatogram of compound 48 (78% ee)



HPLC chromatogram of compound **49** (69% ee)



## HPLC chromatogram of compound 50 (58% ee)



HPLC chromatogram of compound 51 (99% ee)



HPLC chromatogram of compound 52 (92% ee)



HPLC chromatogram of compound 53 (57% ee)



HPLC chromatogram of compound 54 (72% ee)



HPLC chromatogram of compound 55 (70% ee)



HPLC chromatogram of compound 56 (90% ee)



HPLC chromatogram of compound 57 (97% ee)



NO<sub>2</sub> ∠Me N H Br 1500 m 1.483 1250 1000 750 500 · 5.061 250 0 20.0 30.0 ا 15.0 25.0 35.0 45.0 40.0 Ret Time (min) Height (µV) Area (µV.sec) Area (%) # 1 11.483 1175022 23270458 50.077 2 45.061 190944 23198612 49.923 total 1365966 46469070 100.000 500





HPLC chromatogram of compound 59 (59% ee)]





HPLC chromatogram of compound 60 (99% ee)



HPLC chromatogram of compound **61** (62% ee)



HPLC chromatogram of compound 62 (55% ee)
CN NH<sub>2</sub> O 2500 2250 564 2000 534 1750 1500 1250 1000 750 500 250 0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 5.0 min Ret Time (min) Height (µV) Area (µV.sec) # Area (%) 6.564 1856976 49.904 1 23418372 2 7.534 1646764 23508269 50.096 total 3503741 46926641 100.000 2500 2000 1500 1000 500 0 1 5.5 6.0 7.5 6.5 7.0 8.0 8.5 9.5 min 9.0 5.0 Ret Time (min) Height (µV) Area (µV.sec) Area (%) # 6.609 1 114134 1781156 5.522 2 7.547 30475161 94.478 2080142 2194276 32256317 100.000 total

HPLC chromatogram of compound 63 (88% ee)



HPLC chromatogram of compound 64 (89% ee)

HPLC chromatogram of compound 65 (71% ee)



HPLC chromatogram of compound 66 (90% ee)





HPLC chromatogram of compound 67 (96% ee)



HPLC chromatogram of compound 68 (97% ee)

HPLC chromatogram of compound 69 (95% ee)









HPLC chromatogram of compound 71 (88% ee, 6:1 dr)